Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(X)    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: September 30, 2017
OR
( )    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________

Commission File Number: 0-15386
CERNER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
 
43-1196944
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer Identification
Number)
2800 Rockcreek Parkway
North Kansas City, MO
 
64117
(Address of principal executive offices)
 
(Zip Code)
(816) 221-1024
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]     No [  ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes [X]     No [  ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer [X]    Accelerated filer [  ]    Non-accelerated filer [  ] (do not check if smaller reporting company)    Smaller reporting company [  ] Emerging growth company [  ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [  ]      No [X]
Indicate the number of shares outstanding of the issuer's classes of common stock, as of the latest practicable date.
Class
  
Outstanding at October 19, 2017
Common Stock, $0.01 par value per share
  
332,414,896 shares


Table of Contents

CERNER CORPORATION

TABLE OF CONTENTS
 
Part I.
Financial Information:
 
 
 
 
Item 1.
Financial Statements:
 
 
 
 
 
Condensed Consolidated Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016
 
 
 
 
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and October 1, 2016 (unaudited)
 
 
 
 
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2017 and October 1, 2016 (unaudited)
 
 
 
 
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and October 1, 2016 (unaudited)
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
Part II.
Other Information:
 
 
 
 
Item 2.
 
 
 
Item 6.
 
 
 
Signatures
 



Table of Contents

Part I. Financial Information

Item 1. Financial Statements

CERNER CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
As of September 30, 2017 (unaudited) and December 31, 2016
(In thousands, except share data)
2017
 
2016
 
 
 
 
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
573,054

 
$
170,861

Short-term investments
278,996

 
185,588

Receivables, net
1,020,707

 
944,943

Inventory
15,687

 
14,740

Prepaid expenses and other
343,060

 
303,229

Total current assets
2,231,504

 
1,619,361

 
 
 
 
Property and equipment, net
1,587,035

 
1,552,524

Software development costs, net
802,874

 
719,209

Goodwill
851,961

 
844,200

Intangible assets, net
501,299

 
566,047

Long-term investments
112,401

 
109,374

Other assets
145,182

 
219,248

 
 
 
 
Total assets
$
6,232,256

 
$
5,629,963

 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
 
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
204,323

 
$
238,134

Current installments of long-term debt and capital lease obligations
13,988

 
26,197

Deferred revenue
327,622

 
311,839

Accrued payroll and tax withholdings
202,640

 
211,554

Other accrued expenses
58,292

 
57,677

Total current liabilities
806,865

 
845,401

 
 
 
 
Long-term debt and capital lease obligations
521,016

 
537,552

Deferred income taxes and other liabilities
327,340

 
306,263

Deferred revenue
13,032

 
12,800

Total liabilities
1,668,253

 
1,702,016

 
 
 
 
Shareholders’ Equity:
 
 
 
Common stock, $.01 par value, 500,000,000 shares authorized, 356,765,307 shares issued at September 30, 2017 and 353,731,237 shares issued at December 31, 2016
3,568

 
3,537

Additional paid-in capital
1,345,022

 
1,230,913

Retained earnings
4,602,208

 
4,094,327

Treasury stock, 24,452,763 shares at September 30, 2017 and 24,089,737 shares at December 31, 2016
(1,314,054
)
 
(1,290,665
)
Accumulated other comprehensive loss, net
(72,741
)
 
(110,165
)
Total shareholders’ equity
4,564,003

 
3,927,947

 
 
 
 
Total liabilities and shareholders’ equity
$
6,232,256

 
$
5,629,963


See notes to condensed consolidated financial statements (unaudited).

1

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the three and nine months ended September 30, 2017 and October 1, 2016
(unaudited)
 
 
Three Months Ended
 
Nine Months Ended
(In thousands, except per share data)
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Revenues:
 
 
 
 
 
 
 
System sales
$
324,021

 
$
301,252

 
$
991,685

 
$
913,710

Support, maintenance and services
927,829

 
861,085

 
2,763,483

 
2,561,474

Reimbursed travel
24,157

 
22,220

 
73,319

 
63,470

 
 
 
 
 
 
 
 
Total revenues
1,276,007

 
1,184,557

 
3,828,487

 
3,538,654

Costs and expenses:
 
 
 
 
 
 
 
Cost of system sales
105,200

 
93,275

 
322,884

 
296,336

Cost of support, maintenance and services
73,547

 
67,475

 
228,757

 
204,313

Cost of reimbursed travel
24,157

 
22,220

 
73,319

 
63,470

Sales and client service
564,621

 
512,671

 
1,688,208

 
1,534,763

Software development (Includes amortization of $44,358 and $126,346 for the three and nine months ended September 30, 2017, respectively; and $35,552 and $102,429 for the three and nine months ended October 1, 2016, respectively)
153,834

 
136,755

 
442,570

 
405,451

General and administrative
84,178

 
87,071

 
263,203

 
267,232

Amortization of acquisition-related intangibles
22,564

 
22,865

 
68,126

 
68,104

 
 
 
 
 
 
 
 
Total costs and expenses
1,028,101

 
942,332

 
3,087,067

 
2,839,669

 
 
 
 
 
 
 
 
Operating earnings
247,906

 
242,225

 
741,420

 
698,985

 
 
 
 
 
 
 
 
Other income (expense), net
2,509

 
(417
)
 
4,054

 
3,734

 
 
 
 
 
 
 
 
Earnings before income taxes
250,415

 
241,808

 
745,474

 
702,719

Income taxes
(72,991
)
 
(71,829
)
 
(215,154
)
 
(215,926
)
 
 
 
 
 
 
 
 
Net earnings
$
177,424

 
$
169,979

 
$
530,320

 
$
486,793

 
 
 
 
 
 
 
 
Basic earnings per share
$
0.53

 
$
0.50

 
$
1.60

 
$
1.44

Diluted earnings per share
$
0.52

 
$
0.49

 
$
1.57

 
$
1.41

Basic weighted average shares outstanding
331,993

 
338,684

 
331,319

 
338,675

Diluted weighted average shares outstanding
338,780

 
344,817

 
337,946

 
344,917

See notes to condensed consolidated financial statements (unaudited).


2

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the three and nine months ended September 30, 2017 and October 1, 2016
(unaudited)
 
 
Three Months Ended
 
Nine Months Ended
(In thousands)
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Net earnings
$
177,424

 
$
169,979

 
$
530,320

 
$
486,793

Foreign currency translation adjustment and other (net of taxes (benefit) of $(100) and $991 for the three and nine months ended September 30, 2017; and $1,282 and $3,437 for the three and nine months ended October 1, 2016)
10,806

 
(2,085
)
 
37,369

 
(8,557
)
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of $(1) and $34 for the three and nine months ended September 30, 2017; and $(188) and $101 for the three and nine months ended October 1, 2016)
(2
)
 
(308
)
 
55

 
164

 
 
 
 
 
 
 
 
Comprehensive income
$
188,228

 
$
167,586

 
$
567,744

 
$
478,400


See notes to condensed consolidated financial statements (unaudited).


3

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the nine months ended September 30, 2017 and October 1, 2016
(unaudited)
 
Nine Months Ended
(In thousands)
2017
 
2016
 
 
 
 
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net earnings
$
530,320

 
$
486,793

Adjustments to reconcile net earnings to net cash provided by operating activities:
 
 
 
Depreciation and amortization
425,241

 
371,385

Share-based compensation expense
59,217

 
56,896

Provision for deferred income taxes
36,667

 
(25,922
)
Changes in assets and liabilities (net of businesses acquired):
 
 
 
Receivables, net
(19,080
)
 
43,699

Inventory
(909
)
 
(5,590
)
Prepaid expenses and other
(11,908
)
 
(33,801
)
Accounts payable
(12,651
)
 
(19,566
)
Accrued income taxes
1,984

 
53,393

Deferred revenue
12,749

 
(1,780
)
Other accrued liabilities
(62,865
)
 
(17,809
)
 
 
 
 
Net cash provided by operating activities
958,765

 
907,698

 
 
 
 
CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Capital purchases
(262,372
)
 
(327,861
)
Capitalized software development costs
(210,033
)
 
(228,803
)
Purchases of investments
(337,010
)
 
(387,809
)
Sales and maturities of investments
237,912

 
262,100

Purchase of other intangibles
(22,186
)
 
(13,222
)
 
 
 
 
Net cash used in investing activities
(593,689
)
 
(695,595
)
 
 
 
 
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Proceeds from exercise of stock options
61,688

 
60,486

Payments to taxing authorities in connection with shares directly withheld from associates
(7,989
)
 
(38,122
)
Treasury stock purchases
(23,389
)
 
(200,075
)
Contingent consideration payments for acquisition of businesses
(2,671
)
 
(2,074
)
 
 
 
 
Net cash provided by (used in) financing activities
27,639


(179,785
)
 
 
 
 
Effect of exchange rate changes on cash and cash equivalents
9,478

 
(2,943
)
 
 
 
 
Net increase in cash and cash equivalents
402,193

 
29,375

Cash and cash equivalents at beginning of period
170,861

 
402,122

 
 
 
 
Cash and cash equivalents at end of period
$
573,054

 
$
431,497

 
 
 
 
Summary of acquisition transactions:
 
 
 
Fair value of tangible assets acquired
$

 
$
(10,200
)
Fair value of intangible assets acquired

 
(25,000
)
Fair value of goodwill

 
46,940

Less: Fair value of liabilities assumed

 
(11,740
)
 
 
 
 
Net cash used
$

 
$

See notes to condensed consolidated financial statements (unaudited).

4

Table of Contents

CERNER CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
 
(1) Interim Statement Presentation

Basis of Presentation

The condensed consolidated financial statements included herein have been prepared by Cerner Corporation ("Cerner," the "Company," "we," "us" or "our") without audit, pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K.
 
In management’s opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year.

The condensed consolidated financial statements were prepared using GAAP . These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses . Actual results could differ from those estimates.

Fiscal Period End

Our third fiscal quarter ends on the Saturday closest to September 30. The 2017 and 2016 third quarters ended on September 30, 2017 and October 1, 2016, respectively. All references to years in these notes to condensed consolidated financial statements represent the respective three or nine months ended on such dates, unless otherwise noted .

Accounting Pronouncements Adopted in 2017

Share-Based Compensation. In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . ASU 2016-09 impacts several aspects of the accounting for share-based payment award transactions, including: (1) accounting and cash flow classification for excess tax benefits and deficiencies, (2) forfeitures, and (3) tax withholding requirements and cash flow classification . ASU 2016-09 was effective for the Company in the first quarter of 2017. This new guidance impacts our condensed consolidated financial statements as follows:

Prior to the adoption of ASU 2016-09, when associates exercised stock options, or upon the vesting of restricted stock awards, we recognized any related excess tax benefits or deficiencies (the difference between the deduction for tax purposes and the cumulative compensation cost recognized in the consolidated financial statements) in additional paid-in capital ("APIC"). During the three and nine months ended October 1, 2016 , we recognized net excess tax benefits in APIC of $37 million and $48 million , respectively.

Under the new guidance, all excess tax benefits and tax deficiencies are recognized as a component of income tax expense. They are not estimated when determining the annual estimated effective tax rate; instead, they are recorded as discrete items in the reporting period they occur. During the three and nine months ended September 30, 2017 , we recognized $5 million and $22 million , respectively, of net excess tax benefits as discrete items, which are included in income taxes in our condensed consolidated statements of operations. These net excess tax benefits recognized during the three and nine months ended September 30, 2017 , resulted in favorable impacts to diluted earnings per share of $0.01 and $0.06 , respectively.

This provision of the new guidance may have a significant impact on our future income tax expense, including increased variability in our quarterly effective tax rates. The impact will be dependent on a number of factors, including the price of our common stock, grant activity under our stock and equity plans, and the timing of option exercises by our associates. This provision of the new guidance was required to be applied prospectively. Prior periods have not been retrospectively adjusted.

5


We utilize the treasury stock method for calculating diluted earnings per share. Prior to the adoption of ASU 2016-09, this method assumed that any net excess tax benefits generated from the hypothetical exercise of dilutive options were used to repurchase outstanding shares. Assumed share repurchases for net excess tax benefits included in our calculation of diluted earnings per share for the three and nine months ended October 1, 2016 were 2.1 million shares and 2.0 million shares respectively.

Under the new guidance, excess tax benefits generated from the hypothetical exercise of dilutive options are excluded from the calculation of diluted earnings per share. Therefore, the denominator in our diluted earnings per share calculation has increased (comparatively). We estimate that this provision of the new guidance will reduce our calculation of diluted earnings per share by approximately $0.01 to $0.02 for our fiscal year ended December 30, 2017. This provision of the new guidance was required to be applied prospectively. Prior periods have not been retrospectively adjusted.

Prior to the adoption of ASU 2016-09, we presented net excess tax benefits in our condensed consolidated statements of cash flows as a cash inflow from financing activities. Under the new guidance, net excess tax benefits are presented within operating activities. We have elected to apply this provision of the new guidance retrospectively. Prior periods have been retrospectively adjusted.

Prior to the adoption of ASU 2016-09, we presented cash payments to taxing authorities in connection with shares directly withheld from associates upon the exercise of stock options, or upon the vesting of restricted stock awards, to meet statutory tax withholding requirements (employee withholdings) as a cash outflow from operating activities. Under the new guidance, such payments are presented within financing activities. This provision of the new guidance was required to be applied retrospectively. Prior periods have been retrospectively adjusted .

Under the new guidance, an entity is permitted to make an entity-wide accounting policy election (at adoption) either to estimate the number of forfeitures expected to occur or to account for forfeitures as a reduction to compensation cost when they occur. Upon adoption of ASU 2016-09, we did not change our policy of estimating participant forfeitures as a part of our calculations of share-based compensation cost.

Income Taxes. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory , which provides new guidance regarding when an entity should recognize the income tax consequences of certain intra-entity asset transfers. Prior to the adoption of ASU 2016-16, U.S. GAAP prohibited entities from recognizing the income tax consequences of intercompany asset transfers, including transfers of intellectual property. The seller deferred any net tax effect, and the buyer was prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements. ASU 2016-16 requires entities to recognize these tax consequences in the period in which the transfer takes place, with the exception of inventory transfers .

ASU 2016-16 is effective for the Company in the first quarter of 2018, with early adoption permitted in the first quarter of 2017. The standard requires the use of the modified retrospective (cumulative effect) transition approach. The Company adopted the standard early, in the first quarter of 2017. In connection with such adoption, we recorded a cumulative effect adjustment reducing prepaid expenses and other, other assets, and retained earnings within our condensed consolidated balance sheets by $8 million , $14 million , and $22 million , respectively. This cumulative effect adjustment includes recognition of the income tax consequences of intra-entity transfers of assets other than inventory that occurred prior to the adoption date. Prior periods were not retrospectively adjusted.

Recently Issued Accounting Pronouncements

Revenue Recognition. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP .

6


The FASB has issued the following amendments to ASU 2014-09 from August 2015 through September 2017:
ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date
ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)
ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing
ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients
ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers
ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments
Such amendments provide supplemental and clarifying guidance, as well as amend the effective date of the new standard.
ASU 2014-09, as amended, is effective for the Company in the first quarter of 2018, with early adoption permitted in the first quarter of 2017. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method.
In 2015, we formed a cross-functional implementation team and began our analysis of this new guidance. Such analysis includes assessment of the impact of the new guidance on our consolidated financial statements and related disclosures, as well as related impacts on processes, accounting systems, and internal controls. Based on our analysis to-date, we have reached the following tentative conclusions regarding this new guidance and how we expect it to impact our consolidated financial statements and related disclosures:
We will adopt this new guidance effective with our first quarter of 2018.
We will use the cumulative effect transition method. Such method provides that the cumulative effect from prior periods upon applying the new guidance is recognized in our consolidated balance sheets as of the date of adoption, including an adjustment to retained earnings. Prior periods will not be retrospectively adjusted .
We believe substantially all of our revenue falls within the scope of ASU 2014-09, as amended; substantially all of our revenue is contractual.
Generally, our subscription and content fees revenue is recognized ratably over the respective contract terms ("over time"). Upon adoption of the new guidance, we expect to recognize a license component of certain subscription and content fees revenue upon delivery to the customer ("point in time") and a non-license component (i.e. support) of such revenues over the respective contract terms ("over time"). At the date of adoption of this new guidance, we expect to record a cumulative adjustment to our consolidated balance sheet, including an adjustment to retained earnings, to adjust for the impact of certain prior period subscription and content fees revenue, as calculated under the new guidance.
For certain of our arrangements, revenue for software, implementation services and, in certain cases, support services for which vendor specific objective evidence (VSOE) of fair value cannot be established are accounted for as a single unit of accounting. If VSOE of fair value cannot be established for both the implementation services and the support services, the entire arrangement fee is recognized ratably ("over time") over the period during which the implementation services are expected to be performed or the support period, whichever is longer, beginning with delivery of the software, provided that all other revenue recognition criteria are met. Upon adoption of the new guidance, the concept of VSOE of fair value is eliminated. Consideration for an arrangement is allocated to performance obligations based on stand-alone selling price or an estimate of stand-alone selling price. With this change, we expect to be able to allocate consideration to the various elements within arrangements currently accounted for as a single unit of accounting. Such revenue will then be recognized as each performance obligation is delivered (i.e. "point in time" for software) or as provided to the customer (i.e. "over time" for implementation services and support services). At the date of adoption of this new guidance, we expect to record a cumulative adjustment to our consolidated balance sheet, including an adjustment to retained earnings, to adjust for the impact

7


of certain software, implementation services, and support services delivered in prior periods, as calculated under the new guidance.
We have determined the only significant incremental costs incurred to obtain contracts with customers within the scope of ASU 2014-09, as amended, are sales commissions paid to associates. Under current U.S. GAAP, we recognize sales commissions as earned, and record such amounts as a component of total costs and expenses in our consolidated statements of operations. We recognized sales commission expense of $44 million , $45 million and $35 million in the 2016, 2015, and 2014 annual periods, respectively. Under the new guidance, we expect to record sales commissions as an asset, and amortize to expense over the related contract performance period. At the date of adoption of this new guidance, we expect to record an asset in our consolidated balance sheets for the amount of unamortized sales commissions for prior periods, as calculated under the new guidance. Such amount will subsequently be amortized to expense over the remaining performance periods of the related contracts with remaining performance obligations. We currently estimate the amount of this asset to approximate $80 million . Such estimate is preliminary and subject to change as we finalize our implementation process.
In connection with the expected cumulative adjustments described above, we also expect to record a cumulative adjustment to our consolidated balance sheet, including an adjustment to retained earnings, for the related impact on deferred income taxes from such adjustments.
Our analysis and evaluation of the new standard will continue through the effective date in the first quarter of 2018. A significant amount of work remains due to the complexity of revenue recognition within our industry, the increased number of judgments and estimates required by this new guidance, and the volume of our contract portfolio which must be examined. We must quantify all impacts of this new guidance, including the topics discussed above, which may be material to our consolidated financial statements and related disclosures. We must also implement any necessary changes/modifications to processes, accounting systems, and internal controls.

Financial Instruments. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) : Recognition and Measurement of Financial Assets and Financial Liabilities , which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. Such guidance will impact how we account for our investments reported under the cost method of accounting as follows:

Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) will be required to be measured at fair value with changes in fair value recognized in net earnings. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

The impairment assessment of equity investments without readily determinable fair values will require a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.

ASU 2016-01 is effective for the Company in the first quarter of 2018, with early adoption permitted. We do not expect the adoption of ASU 2016-01 to have a material impact on our consolidated financial statements and related disclosures, and we have determined that we will not early adopt.

Leases. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) , which introduces a new model that requires most leases to be reported on the balance sheet and aligns many of the underlying principles of the new lessor model with those in the new revenue recognition standard. The standard requires the use of the modified retrospective (cumulative effect) transition approach. ASU 2016-02 is effective for the Company in the first quarter of 2019, with early adoption permitted. We are currently evaluating the effect that ASU 2016-02 will have on our consolidated financial statements and related disclosures, and we do not expect to early adopt.

Credit Losses on Financial Instruments. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which provides new guidance regarding the measurement and recognition of credit impairment for certain financial assets. Such guidance will impact how we determine our allowance for estimated uncollectible receivables and evaluate our available-for-sale investments for impairment. ASU 2016-13 is effective for the Company in the first quarter of 2020, with early adoption permitted in the first quarter of 2019. We are currently evaluating the effect that ASU 2016-13 will have on our consolidated financial statements and related disclosures, and we have not determined if we will early adopt.

8



Callable Debt Securities. In March 2017, the FASB issued ASU 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities , which shortens the amortization period for certain investments in callable debt securities purchased at a premium by requiring the premium be amortized to the earliest call date. Such guidance will impact how premiums are amortized on our available-for-sale investments. ASU 2017-08 is effective for the Company in the first quarter of 2019, with early adoption permitted. The standard requires the use of the modified retrospective (cumulative effect) transition approach. We are currently evaluating the effect that ASU 2017-08 will have on our consolidated financial statements and related disclosures, and we have not determined if we will early adopt .

9


(2) Fair Value Measurements

We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
 
Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table details our financial assets measured and recorded at fair value on a recurring basis at September 30, 2017 :
(In thousands)
 
 
 
 
 
 

 
Fair Value Measurements Using
Description
 
Balance Sheet Classification
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
Money market funds
 
Cash equivalents
 
$
319,668

 
$

 
$

Time deposits
 
Cash equivalents
 

 
51,426

 

Commercial paper
 
Cash equivalents
 

 
23,550

 

Government and corporate bonds
 
Cash equivalents
 

 
500

 

Time deposits
 
Short-term investments
 

 
32,808

 

Commercial paper
 
Short-term investments
 

 
87,874

 

Government and corporate bonds
 
Short-term investments
 

 
158,314

 

Government and corporate bonds
 
Long-term investments
 

 
99,032

 


The following table details our financial assets measured and recorded at fair value on a recurring basis at December 31, 2016 :
(In thousands)
 
 
 
 
 
 
 
 
Fair Value Measurements Using
Description
 
Balance Sheet Classification
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
Money market funds
 
Cash equivalents
 
$
23,110

 
$

 
$

Time deposits
 
Cash equivalents
 

 
11,477

 

Time deposits
 
Short-term investments
 

 
40,639

 

Commercial paper
 
Short-term investments
 

 
22,301

 

Government and corporate bonds
 
Short-term investments
 

 
122,648

 

Government and corporate bonds
 
Long-term investments
 

 
95,368

 

We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt, including current maturities, at September 30, 2017 and December 31, 2016 was approximately $517 million and $515 million , respectively. The carrying amount of such debt at both September 30, 2017 and December 31, 2016 was $500 million .

10


(3) Available-for-sale Investments

Available-for-sale investments at September 30, 2017 were as follows:
(In thousands)
 
Adjusted Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
 
Money market funds
 
$
319,668

 
$

 
$

 
$
319,668

Time deposits
 
51,426

 

 

 
51,426

Commercial paper
 
23,550

 

 

 
23,550

Government and corporate bonds
 
500

 

 

 
500

Total cash equivalents
 
395,144

 

 

 
395,144

 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
Time deposits
 
32,808

 

 

 
32,808

Commercial paper
 
87,916

 
2

 
(44
)
 
87,874

Government and corporate bonds
 
158,532

 
2

 
(220
)
 
158,314

Total short-term investments
 
279,256

 
4

 
(264
)
 
278,996

 
 
 
 
 
 
 
 
 
Long-term investments:
 
 
 
 
 
 
 
 
Government and corporate bonds
 
99,226

 

 
(194
)
 
99,032

 
 
 
 
 
 
 
 
 
Total available-for-sale investments
 
$
773,626


$
4


$
(458
)

$
773,172


Available-for-sale investments at December 31, 2016 were as follows:
(In thousands)
 
Adjusted Cost
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Fair Value
 
 
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
 
Money market funds
 
$
23,110

 
$

 
$

 
$
23,110

Time deposits
 
11,477

 

 

 
11,477

Total cash equivalents
 
34,587

 

 

 
34,587

 
 
 
 
 
 
 
 
 
Short-term investments:
 
 
 
 
 
 
 
 
Time deposits
 
40,639

 

 

 
40,639

Commercial paper
 
22,325

 

 
(24
)
 
22,301

Government and corporate bonds
 
122,729

 
3

 
(84
)
 
122,648

Total short-term investments
 
185,693

 
3

 
(108
)
 
185,588

 
 
 
 
 
 
 
 
 
Long-term investments:
 
 
 
 
 
 
 
 
Government and corporate bonds
 
95,806

 

 
(438
)
 
95,368

 
 
 
 
 
 
 
 
 
Total available-for-sale investments
 
$
316,086

 
$
3

 
$
(546
)
 
$
315,543


We sold available-for-sale investments for proceeds of $29 million and $92 million during the nine months ended September 30, 2017 and October 1, 2016 , respectively, resulting in insignificant gains in each period.

11


(4) Receivables

A summary of net receivables is as follows:
(In thousands)
September 30, 2017
 
December 31, 2016
 
 
 
 
Gross accounts receivable
$
1,065,903

 
$
958,843

Less: Allowance for doubtful accounts
59,673

 
43,028

 
 
 
 
Accounts receivable, net of allowance
1,006,230

 
915,815

 
 
 
 
Current portion of lease receivables
14,477

 
29,128

 
 
 
 
Total receivables, net
$
1,020,707

 
$
944,943


During the second quarter of 2008, Fujitsu Services Limited’s ("Fujitsu") contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England was terminated. This had the effect of our subcontract for the project being terminated. We continue to be in dispute with Fujitsu regarding Fujitsu’s obligation to pay the amounts comprised of accounts receivable and contracts receivable related to that subcontract, and we are working with Fujitsu to resolve these issues based on processes provided for in the contract. Part of that process requires final resolution of disputes between Fujitsu and the NHS regarding the contract termination. As of September 30, 2017 , it remains unlikely that our matter with Fujitsu will be resolved in the next 12 months. Therefore, these receivables have been classified as long-term and represent less than the majority of other long-term assets at September 30, 2017 and December 31, 2016 . While the ultimate collectability of the receivables pursuant to this process is uncertain, we believe that we have valid and equitable grounds for recovery of such amounts and that collection of recorded amounts is probable. Nevertheless, it is reasonably possible that our estimates regarding collectability of such amounts might materially change in the near term, considering that we do not have complete knowledge of the status of the proceedings between Fujitsu and NHS and their effect on our claim.

During the first nine months of 2017 and 2016 , we received total client cash collections of $4.1 billion and $3.8 billion , respectively.
 
(5) Income Taxes

We determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.

Our effective tax rate was 28.9% and 30.7% for the first nine months of 2017 and 2016 , respectively. The decrease in the effective tax rate in 2017 is primarily a result of the inclusion of net excess tax benefits as a discrete item within the tax provision, upon our adoption of ASU 2016-09 in the first quarter of 2017. Refer to Note (1) for further discussion regarding our adoption of ASU 2016-09 and its impact on our condensed consolidated financial statements.


12


(6) Earnings Per Share

A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows:
 
Three Months Ended
 
2017
 
2016
 
Earnings
 
Shares
 
Per-Share
 
Earnings
 
Shares
 
Per-Share
(In thousands, except per share data)
(Numerator)
 
(Denominator)
 
Amount
 
(Numerator)
 
(Denominator)
 
Amount
 
 
 
 
 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
 
 
 
 
 
Income available to common shareholders
$
177,424

 
331,993

 
$
0.53

 
$
169,979

 
338,684

 
$
0.50

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Stock options and non-vested shares

 
6,787

 
 
 

 
6,133

 
 
Diluted earnings per share:
 
 
 
 
 
 
 
 
 
 
 
Income available to common shareholders including assumed conversions
$
177,424

 
338,780

 
$
0.52

 
$
169,979

 
344,817

 
$
0.49


For the three months ended September 30, 2017 and October 1, 2016 , options to purchase 11.0 million and 8.1 million shares of common stock at per share prices ranging from $50.04 to $73.40 and $47.84 to $73.40 , respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.
 
Nine Months Ended
 
2017
 
2016
 
Earnings
 
Shares
 
Per-Share
 
Earnings
 
Shares
 
Per-Share
(In thousands, except per share data)
(Numerator)
 
(Denominator)
 
Amount
 
(Numerator)
 
(Denominator)
 
Amount
 
 
 
 
 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
 
 
 
 
 
Income available to common shareholders
$
530,320

 
331,319

 
$
1.60

 
$
486,793

 
338,675

 
$
1.44

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Stock options and non-vested shares

 
6,627

 
 
 

 
6,242

 
 
Diluted earnings per share:
 
 
 
 
 
 
 
 
 
 
 
Income available to common shareholders including assumed conversions
$
530,320

 
337,946

 
$
1.57

 
$
486,793

 
344,917

 
$
1.41


For the nine months ended September 30, 2017 and October 1, 2016 , options to purchase 10.4 million and 7.2 million shares of common stock at per share prices ranging from $47.38 to $73.40 and $47.38 to $73.40 , respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.


13


(7) Share-Based Compensation and Equity

Stock Options

Stock option activity for the nine months ended September 30, 2017 was as follows:
(In thousands, except per share data)
Number of
Shares
 
Weighted-
Average
Exercise 
Price
 
Aggregate
Intrinsic 
Value
 
Weighted-Average      
Remaining      
Contractual
 Term (Yrs)      
Outstanding at beginning of year
23,601

 
$
40.33

 
 
 
 
Granted
4,194

 
63.25

 
 
 
 
Exercised
(2,685
)
 
25.03

 
 
 
 
Forfeited and expired
(850
)
 
57.35

 
 
 
 
Outstanding as of September 30, 2017
24,260

 
45.39

 
$
629,257

 
5.99
 
 
 
 
 
 
 
 
Exercisable as of September 30, 2017
12,802

 
$
32.88

 
$
492,125

 
3.82

The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the nine months ended September 30, 2017 were as follows:
Expected volatility (%)
 
26.7
%
Expected term (yrs)
 
7

Risk-free rate (%)
 
2.1
%
Fair value per option
 
$
20.47

As of September 30, 2017 , there was $167 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 3.46 years.
Non-vested Shares and Share Units

Non-vested share and share unit activity for the nine months ended September 30, 2017 was as follows:
(In thousands, except per share data)
Number of Shares
 
Weighted-Average
Grant Date Fair Value
 
 
 
 
Outstanding at beginning of year
354

 
$
61.12

Granted
586

 
66.86

Vested
(158
)
 
57.79

Forfeited
(10
)
 
57.02

 
 
 
 
Outstanding as of September 30, 2017
772

 
$
66.21

As of September 30, 2017 , there was $36 million of total unrecognized compensation cost related to non-vested share awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.65 years.

14


Share-Based Compensation Cost

The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan:
 
Three Months Ended
 
Nine Months Ended
(In thousands)
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Stock option and non-vested share and share unit compensation expense
$
19,858

 
$
18,942

 
$
59,217

 
$
56,896

Associate stock purchase plan expense
1,546

 
1,503

 
4,516

 
4,722

Amounts capitalized in software development costs, net of amortization
(45
)
 
(95
)
 
(365
)
 
(486
)
 
 
 
 
 
 
 
 
Amounts charged against earnings, before income tax benefit
$
21,359

 
$
20,350

 
$
63,368

 
$
61,132

 
 
 
 
 
 
 
 
Amount of related income tax benefit recognized in earnings
$
6,226

 
$
6,045

 
$
18,289

 
$
18,793


Treasury Stock

In May 2017, our Board of Directors authorized a new share repurchase program that allows the Company to repurchase shares of our common stock up to $500 million , excluding transaction costs. The repurchases are to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers. No time limit was set for the completion of this program.

During the nine months ended September 30, 2017 , we repurchased 0.4 million shares for consideration of $23 million . These shares were recorded as treasury stock and accounted for under the cost method. No repurchased shares have been retired. As of September 30, 2017 , an aggregate of $577 million remained available for repurchase under our share repurchase programs.

(8) Contingencies

We accrue estimates for resolution of any legal and other contingencies when losses are probable and estimable, in accordance with Accounting Standards Codification Topic 450, Contingencies .

The terms of our software license agreements with our clients generally provide for a limited indemnification of such clients against losses, expenses and liabilities arising from third party claims based on alleged infringement by our solutions of an intellectual property right of such third party. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include a right to replace or modify an infringing solution. To date, we have not had to reimburse any of our clients for any judgments or settlements to third parties related to these indemnification provisions pertaining to intellectual property infringement claims. For several reasons, including the lack of a sufficient number of prior indemnification claims and the lack of a monetary liability limit for certain infringement cases under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions.

In addition to commitments and obligations in the ordinary course of business, we are subject to various legal proceedings and claims that arise in the ordinary course of business, including for example, employment and client disputes and litigation alleging solution and implementation defects, personal injury, intellectual property infringement, violations of law and breaches of contract and warranties. In addition, we are a defendant in lawsuits filed in federal and state courts brought as putative class or collective actions on behalf of various groups of current and former associates in the U.S. alleging that we misclassified associates as exempt from overtime pay under the Fair Labor Standards Act and state wage and hour laws. These proceedings are at various procedural stages and seek unspecified monetary damages, injunctive relief, costs and attorneys’ fees. Given the substantial uncertainties, such as the impact of discovery and the extent to which significant factual issues are resolved, the disposition of pre-trial motions, the extent of potential damages that are often unspecified or indeterminate, and the status of settlement discussions (if any), we cannot predict with any reasonable certainty the timing or outcome of such contingencies. At this time, we do not believe any material losses under these claims to be probable or estimable.

No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available

15


to our management at the time the judgment is made. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition.

(9) Segment Reporting

We have two operating segments, Domestic and Global. Revenues are derived primarily from the sale of clinical, financial and administrative information systems and solutions. The cost of revenues includes the cost of third party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, acquisition costs and related adjustments, share-based compensation expense, and certain amortization and depreciation. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Interim Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis.

The following table presents a summary of our operating segments and other expense for the three and nine months ended September 30, 2017 and October 1, 2016 :
(In thousands)
Domestic
 
Global    
 
Other    
 
Total    
 
 
 
 
 
 
 
 
Three Months Ended 2017
 
 
 
 
 
 
 
Revenues
$
1,133,971

 
$
142,036

 
$

 
$
1,276,007

 
 
 
 
 
 
 
 
Cost of revenues
176,198

 
26,706

 

 
202,904

Operating expenses
502,256

 
68,229

 
254,712

 
825,197

Total costs and expenses
678,454

 
94,935


254,712

 
1,028,101

 
 
 
 
 
 
 
 
Operating earnings (loss)
$
455,517

 
$
47,101

 
$
(254,712
)
 
$
247,906

(In thousands)
Domestic
 
Global    
 
Other    
 
Total    
 
 
 
 
 
 
 
 
Three Months Ended 2016
 
 
 
 
 
 
 
Revenues
$
1,055,037

 
$
129,520

 
$

 
$
1,184,557

 
 
 
 
 
 
 
 
Cost of revenues
161,625

 
21,345

 

 
182,970

Operating expenses
446,704

 
60,430

 
252,228

 
759,362

Total costs and expenses
608,329

 
81,775

 
252,228

 
942,332

 
 
 
 
 
 
 
 
Operating earnings (loss)
$
446,708

 
$
47,745

 
$
(252,228
)
 
$
242,225

(In thousands)
Domestic
 
Global    
 
Other    
 
Total    
 
 
 
 
 
 
 
 
Nine Months Ended 2017
 
 
 
 
 
 
 
Revenues
$
3,421,429

 
$
407,058

 
$

 
$
3,828,487

 
 
 
 
 
 
 
 
Cost of revenues
549,895

 
75,065

 

 
624,960

Operating expenses
1,474,591

 
197,333

 
790,183

 
2,462,107

Total costs and expenses
2,024,486

 
272,398

 
790,183

 
3,087,067

 
 
 
 
 
 
 
 
Operating earnings (loss)
$
1,396,943

 
$
134,660

 
$
(790,183
)
 
$
741,420


16


(In thousands)
Domestic
 
Global    
 
Other    
 
Total    
 
 
 
 
 
 
 
 
Nine Months Ended 2016
 
 
 
 
 
 
 
Revenues
$
3,132,566

 
$
406,088

 
$

 
$
3,538,654

 
 
 
 
 
 
 
 
Cost of revenues
488,404

 
75,715

 

 
564,119

Operating expenses
1,304,731

 
183,824

 
786,995

 
2,275,550

Total costs and expenses
1,793,135

 
259,539

 
786,995

 
2,839,669

 
 
 
 
 
 
 
 
Operating earnings (loss)
$
1,339,431

 
$
146,549

 
$
(786,995
)
 
$
698,985



17


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following Management Discussion and Analysis ("MD&A") is intended to help the reader understand the results of operations and financial condition of Cerner Corporation ("Cerner," the "Company," "we," "us" or "our"). This MD&A is provided as a supplement to, and should be read in conjunction with, our condensed consolidated financial statements and the accompanying notes to condensed consolidated financial statements ("Notes") found above.

Our third fiscal quarter ends on the Saturday closest to September 30. The 2017 and 2016 third quarters ended on September 30, 2017 and October 1, 2016 , respectively. All references to years in this MD&A represent the respective three or nine months ended on such dates, unless otherwise noted.
 
Except for the historical information and discussions contained herein, statements contained in this quarterly report on Form 10-Q may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. These statements can often be identified by the use of forward-looking terminology, such as "could," "should," "will," "intended," "continue," "believe," "may," "expect," "hope," "anticipate," "goal," "forecast," "plan," "guidance," "opportunity," "prospects" or "estimate" or the negative of these words, variations thereof or similar expressions. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including without limitation: the possibility of significant costs and reputational harm related to product-related liabilities; potential claims for system errors and warranties; the possibility of interruption at our data centers or client support facilities; the possibility of increased expenses, exposure to legal claims and regulatory actions and reputational harm associated with a cyberattack or other breach in our IT security; our proprietary technology may be subject to claims for infringement or misappropriation of intellectual property rights of others, or may be infringed or misappropriated by others; potential claims or other risks associated with relying on open source software in our proprietary software, solutions or services; material adverse resolution of legal proceedings; risks associated with our global operations; risks associated with fluctuations in foreign currency exchange rates; the potential for tax legislation initiatives that could adversely affect our tax position and/or challenges to our tax positions in the U.S. and non-U.S. countries; the uncertainty surrounding the impact of the United Kingdom’s vote to leave the European Union (commonly referred to as Brexit) on our global business; risks associated with the unexpected loss or recruitment and retention of key personnel, failure to successfully develop and execute succession planning to assure transitions of key associates and their knowledge, relationships and expertise, and uncertainties as to how quickly we are able to finalize our CEO succession plans; risks related to our dependence on strategic partners and third party suppliers; difficulties and operational and financial risks associated with successfully completing the integration of the Cerner Health Services (formerly Siemens Health Services) business into our business or the failure to realize the synergies and other benefits expected from the acquisition; risks inherent with business acquisitions and combinations and the integration thereof; the potential for losses resulting from asset impairment charges; risks associated with volatility and disruption resulting from global economic or market conditions; managing growth in the new markets in which we offer solutions, health care devices or services; risks inherent in contracting with government clients; risks associated with our outstanding and future indebtedness, such as compliance with restrictive covenants, which may limit our flexibility to operate our business; changing political, economic, regulatory and judicial influences, which could impact the purchasing practices and operations of our clients and increase costs to deliver compliant solutions and services; government regulation; significant competition and our ability to quickly respond to market changes and changing technologies and to bring competitive new solutions, devices, features and services to market in a timely fashion; long sales cycles for our solutions and services; variations in our quarterly operating results; potential variations in our sales forecasts compared to actual sales; volatility in the trading price of our common stock and the timing and volume of market activity; our directors' authority to issue preferred stock and the anti-takeover provisions in our corporate governance documents; changes in accounting standards issued by the Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements; and, other risks, uncertainties and factors discussed elsewhere in this Form 10-Q, in our other filings with the Securities and Exchange Commission, including those under the caption "Risk Factors" in our latest annual report on Form 10-K, or in materials incorporated herein or therein by reference. Forward-looking statements are not guarantees of future performance or results. The reader should not place undue reliance on forward-looking statements since the statements speak only as of the date they are made. Except as required by law, we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in our results of operations, financial condition or business over time.


18

Table of Contents

Management Overview
Our revenues are primarily derived by selling, implementing and supporting software solutions, clinical content, hardware, devices and services that give health care providers and other stakeholders secure access to clinical, administrative and financial data in real or near-real time, helping them to improve quality, safety and efficiency in the delivery of health care.

Our fundamental strategic focus is the creation of organic growth by investing in research and development ("R&D") to create solutions and services for the health care industry. This strategy has driven strong growth over the long-term, as reflected in five- and ten-year compound annual revenue growth rates of 13% or more. This growth has also created an important strategic footprint in health care, with Cerner ® solutions in more than 25,000 facilities worldwide, including hospitals, physician practices, laboratories, ambulatory centers, behavioral health centers, cardiac facilities, radiology clinics, surgery centers, extended care facilities, retail pharmacies, and employer sites. Selling additional solutions and services back into this client base is an important element of our future revenue growth. We are also focused on driving growth through market share expansion by strategically aligning with health care providers that have not yet selected a supplier and by displacing competitors in health care settings that are looking to replace their current supplier. We may also supplement organic growth with acquisitions or strategic investments.

We expect to drive growth through solutions and services that reflect our ongoing ability to innovate and expand our reach into health care. Examples of these include our CareAware ® health care device architecture and devices, Cerner ITWorks SM services, revenue cycle solutions and services, and HealtheIntent SM population health solutions and services. Finally, we believe there is significant opportunity for growth outside of the United States, with many non-U.S. markets focused on health care information technology as part of their strategy to improve the quality and lower the cost of health care.

Beyond our strategy for driving revenue growth, we are also focused on earnings growth. Similar to our history of growing revenue, our net earnings have increased at compound annual rates of 15% or more over the most recent five- and ten-year periods. We expect to drive continued earnings growth through ongoing revenue growth coupled with margin expansion, which we expect to achieve through efficiencies in our implementation and operational processes and by leveraging R&D investments and controlling general and administrative expenses.

We are also focused on continuing to deliver strong levels of cash flow, which we expect to accomplish by continuing to grow earnings and prudently managing capital expenditures.

Results Overview
The Company delivered lower than expected bookings and good levels of revenues, earnings, and operating cash flow in the third quarter of 2017 .

Bookings, which reflects the value of executed contracts for software, hardware, professional services and managed services, was $1.11 billion in the third quarter of 2017 , which is a decrease of 23% compared to $1.43 billion in the third quarter of 2016 . The decline in bookings was primarily attributable to several large contracts not signing during the quarter as previously expected. These contracts were primarily related to our ITWorks business, which includes large long-term services contracts that have a significant impact on bookings, but do not have a material impact on current period revenue or earnings. The Company still expects to sign these contracts in future periods.

Revenues for the third quarter of 2017 increased 8% to $1.3 billion , compared to $1.2 billion in the third quarter of 2016 . The year-over-year increase in revenue reflects ongoing demand from new and existing clients for Cerner's solutions and services driven by their needs to keep up with regulatory requirements, adapt to changing reimbursement models, and deliver safer and more efficient care.

Net earnings for the third quarter of 2017 increased 4% to $177 million , compared to $170 million in the third quarter of 2016 . Diluted earnings per share increased 6% to $0.52 , compared to $0.49 in the third quarter of 2016 . The overall increase in net earnings and diluted earnings per share was primarily a result of increased revenues.

We had cash collections of receivables of $1.4 billion in the third quarter of 2017 , compared to $1.3 billion in the third quarter of 2016 . Days sales outstanding was 73 days for the third quarter of 2017 compared to 73 days for the second quarter of 2017 and 76 days for the third quarter of 2016 . Operating cash flows for the third quarter of 2017 were $363 million compared to $311 million in the third quarter of 2016 .


19

Table of Contents

Results of Operations
Three Months Ended September 30, 2017 Compared to Three Months Ended October 1, 2016
The following table presents a summary of the operating information for the third quarters of 2017 and 2016 :
(In thousands)
2017
 
% of
Revenue
 
2016
 
% of
Revenue
 
% Change  
Revenues
 
 
 
 
 
 
 
 
 
System sales
$
324,021

 
25
%
 
$
301,252

 
25
%
 
8
 %
Support and maintenance
263,361

 
21
%
 
253,425

 
21
%
 
4
 %
Services
664,468

 
52
%
 
607,660

 
51
%
 
9
 %
Reimbursed travel
24,157

 
2
%
 
22,220

 
2
%
 
9
 %
 
 
 
 
 
 
 
 
 
 
Total revenues
1,276,007

 
100
%
 
1,184,557

 
100
%
 
8
 %
 
 
 
 
 
 
 
 
 
 
Costs of revenue
 
 
 
 
 
 
 
 
 
Costs of revenue
202,904

 
16
%
 
182,970

 
15
%
 
11
 %
 
 
 
 
 
 
 
 
 
 
Total margin
1,073,103

 
84
%
 
1,001,587

 
85
%
 
7
 %
 
 
 
 
 
 
 
 
 
 
Operating expenses
 
 
 
 
 
 
 
 
 
Sales and client service
564,621

 
44
%
 
512,671

 
43
%
 
10
 %
Software development
153,834

 
12
%
 
136,755

 
12
%
 
12
 %
General and administrative
84,178

 
7
%
 
87,071

 
7
%
 
(3
)%
Amortization of acquisition-related intangibles
22,564

 
2
%
 
22,865

 
2
%
 
(1
)%
 
 
 
 
 
 
 
 
 
 
Total operating expenses
825,197

 
65
%
 
759,362

 
64
%
 
9
 %
 
 
 
 
 
 
 
 
 
 
Total costs and expenses
1,028,101

 
81
%
 
942,332

 
80
%
 
9
 %
 
 
 
 
 
 
 
 
 
 
Operating earnings
247,906

 
19
%
 
242,225

 
20
%
 
2
 %
 
 
 
 
 
 
 
 
 
 
Other income (expense), net
2,509

 
 
 
(417
)
 
 
 
 
Income taxes
(72,991
)
 
 
 
(71,829
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net earnings
$
177,424

 
 
 
$
169,979

 
 
 
4
 %
Revenues & Backlog
Revenues increased 8% to $1.3 billion in the third quarter of 2017 , as compared to $1.2 billion in the same period of 2016 .
 
System sales, which include revenues from the sale of licensed software (including perpetual license sales and software as a service), technology resale (hardware, devices, and sublicensed software), deployment period licensed software upgrade rights, installation fees, transaction processing and subscriptions, increased 8% to $324 million in the third quarter of 2017 , from $301 million in the same period of 2016 . The increase in system sales was primarily driven by increases in licensed software and subscriptions of $15 million and $12 million, respectively.
Support and maintenance revenues increased 4% to $263 million in the third quarter of 2017 , from $253 million in the same period of 2016 . This increase was primarily attributable to continued success selling Cerner Millennium ® applications and implementing them at client sites.
Services revenue, which includes professional services (excluding installation) and managed services, increased 9% to $664 million in the third quarter of 2017 , from $608 million in the same period of 2016 . This increase was driven by a $42 million increase in professional services due to growth in implementation and consulting activities and growth in managed services of $15 million as a result of continued demand for our hosting services.

Revenue backlog, which reflects contracted revenue that has not yet been recognized as revenue, increased 7% to $16.5 billion in the third quarter of 2017 compared to $15.5 billion in the same period of 2016 . This increase was driven by solid levels of new business bookings during the past four quarters, including strong levels of managed services bookings that typically have longer contract terms.

20

Table of Contents

Costs of Revenue
Costs of revenue as a percent of total revenues were 16% in the third quarter of 2017 , compared to 15% in the same period of 2016 . The marginally higher costs of revenue as a percent of total revenues was primarily due to higher third-party costs associated with technology resale.
Costs of revenue include the cost of reimbursed travel expense, sales commissions, third party consulting services and subscription content and computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Such costs, as a percent of total revenues, typically have varied as the mix of revenue (software, hardware, devices, maintenance, support, services and reimbursed travel) carrying different margin rates changes from period to period. Costs of revenue does not include the costs of our client service personnel who are responsible for delivering our service offerings. Such costs are included in sales and client service expense.
Operating Expenses
Total operating expenses increased 9% to $825 million in the third quarter of 2017 , as compared to $759 million in the same period of 2016 .
 
Sales and client service expenses as a percent of total revenues were 44% in the third quarter of 2017 , compared to 43% in the same period of 2016 . These expenses increased 10% to $565 million in the third quarter of 2017 , from $513 million in the same period of 2016 . Sales and client service expenses include salaries and benefits of sales, marketing, support, and services personnel, depreciation and other expenses associated with our managed services business, communications expenses, unreimbursed travel expenses, expense for share-based payments, and trade show and advertising costs. The growth in sales and client service expenses reflects hiring of services personnel to support the growth in services revenue.
Software development expenses as a percent of total revenues were 12% in the third quarter of both 2017 and 2016 . Expenditures for software development include ongoing development and enhancement of the Cerner Millennium and HealtheIntent platforms, with a focus on supporting key initiatives to enhance physician experience, revenue cycle and population health solutions. A summary of our total software development expense in the third quarters of 2017 and 2016 is as follows:
 
Three Months Ended
(In thousands)
2017
 
2016
 
 
 
 
Software development costs
$
176,543

 
$
174,831

Capitalized software costs
(66,404
)
 
(72,943
)
Capitalized costs related to share-based payments
(663
)
 
(685
)
Amortization of capitalized software costs
44,358

 
35,552

 
 
 
 
Total software development expense
$
153,834

 
$
136,755

 
General and administrative expenses as a percent of total revenues were 7% in the third quarter of both 2017 and 2016 . These expenses decreased 3% to $84 million in the third quarter of 2017 , from $87 million in the same period of 2016 . General and administrative expenses include salaries and benefits for corporate, financial and administrative staffs, utilities, communications expenses, professional fees, depreciation and amortization, transaction gains or losses on foreign currency, expense for share-based payments, acquisition costs and related adjustments. The decrease in general and administrative expenses is primarily due to lower expense for share-based payments, driven by stock option awards forfeited by our former CEO upon his passing in July 2017.

Amortization of acquisition-related intangibles as a percent of total revenues were 2% in the third quarter of both 2017 and 2016 . These expenses remained flat at $23 million in the third quarter of both 2017 and 2016 . Amortization of acquisition-related intangibles includes the amortization of customer relationships, acquired technology, trade names, and non-compete agreements recorded in connection with our business acquisitions.


21

Table of Contents

Non-Operating Items
 
Other income (expense), net was $3 million in income in the third quarter of 2017 , and less than $1 million in expense in the same period of 2016 . The increase is primarily attributable to an impairment loss recognized on one of our investments accounted for under the cost method in the third quarter of 2016.

Our effective tax rate was 29.1% for the third quarter of 2017 and 29.7% in the same period of 2016 . The decrease in the effective tax rate in 2017 is primarily a result of the inclusion of net excess tax benefits as discrete items within the tax provision, upon our adoption of ASU 2016-09 in the first quarter of 2017 . Refer to Note (1) of the notes to condensed consolidated financial statements for further discussion regarding our adoption of ASU 2016-09 and its impact on our condensed consolidated financial statements.

Operations by Segment
We have two operating segments: Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The Global segment includes revenue contributions and expenditures linked to business activity in Aruba, Australia, Austria, the Bahamas, Belgium, Bermuda, Brazil, Canada, Cayman Islands, Chile, Denmark, Egypt, England, Finland, France, Germany, Guam, India, Ireland, Kuwait, Luxembourg, Malaysia, Mexico, Netherlands, Norway, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland and the United Arab Emirates. Refer to Note (9) of the notes to condensed consolidated financial statements for further information regarding our reportable segments.

The following table presents a summary of our operating segment information for the third quarters of 2017 and 2016 :  
(In thousands)
2017
 
% of Revenue
 
2016
 
% of Revenue
 
% Change  
 
 
 
 
 
 
 
 
 
 
Domestic Segment
 
 
 
 
 
 
 
 
 
Revenues
$
1,133,971

 
100%
 
$
1,055,037

 
100%
 
7%
 
 
 
 
 
 
 
 
 
 
Costs of revenue
176,198

 
16%
 
161,625

 
15%
 
9%
Operating expenses
502,256

 
44%
 
446,704

 
42%
 
12%
Total costs and expenses
678,454

 
60%
 
608,329

 
58%
 
12%
 
 
 
 
 
 
 
 
 
 
Domestic operating earnings
455,517

 
40%

446,708

 
42%
 
2%
 
 
 
 
 
 
 
 
 
 
Global Segment
 
 
 
 
 
 
 
 
 
Revenues
142,036

 
100%
 
129,520

 
100%
 
10%
 
 
 
 
 
 
 
 
 
 
Costs of revenue
26,706

 
19%
 
21,345

 
16%
 
25%
Operating expenses
68,229

 
48%
 
60,430

 
47%
 
13%
Total costs and expenses
94,935

 
67%
 
81,775

 
63%
 
16%
 
 
 
 
 
 
 
 
 
 
Global operating earnings
47,101

 
33%
 
47,745

 
37%
 
(1)%
 
 
 
 
 
 
 
 
 
 
Other, net
(254,712
)
 
 
 
(252,228
)
 
 
 
1%
 
 
 
 
 
 
 
 
 
 
Consolidated operating earnings
$
247,906

 
 
 
$
242,225

 
 
 
2%
Domestic Segment
Revenues increased 7% to $1.13 billion in the third quarter of 2017 , from $1.06 billion in the same period of 2016 . This increase was primarily driven by growth in services revenue.
Costs of revenue as a percent of revenues was 16% in the third quarter of 2017 compared to 15% in the same period of 2016 . The marginally higher costs of revenue as a percent of revenues was primarily due to higher third-party costs associated with technology resale.
Operating expenses as a percent of revenues were 44% in the third quarter of 2017 , compared to 42% in the same period of 2016 . The increase as a percent of revenues reflects a higher mix of services during the third quarter of 2017 that was driven by services revenue growth.


22

Table of Contents

Global Segment
Revenues increased 10% to $142 million in the third quarter of 2017 , from $130 million in the same period of 2016 . This increase was primarily driven by growth in services revenue.
Costs of revenue as a percent of revenues were 19% in the third quarter of 2017 , compared to 16% in the same period of 2016 . The higher costs of revenue as a percent of revenues were primarily driven by a higher amount of third party resources utilized for support and services.
Operating expenses as a percent of revenues were 48% in the third quarter of 2017 , compared to 47% in the same period of 2016 . The increase as a percent of revenues was primarily due to an increase in non-personnel expenses.

Other, net
Operating results not attributed to an operating segment include expenses such as software development, general and administrative expenses, acquisition costs and related adjustments, share-based compensation expense, and certain amortization and depreciation. These expenses increased 1% to $255 million in the third quarter of 2017 , from $252 million in the same period of 2016 . The increase was primarily due to increased amortization of capitalized software costs, resulting from releases of new and enhanced solutions over the last four quarters.

Nine Months Ended September 30, 2017 Compared to Nine Months Ended October 1, 2016
The following table presents a summary of our operating information for the first nine months of 2017 and 2016 :
(In thousands)
2017
 
% of
Revenue
 
2016
 
% of
Revenue
 
% Change  
Revenues
 
 
 
 
 
 
 
 
 
System sales
$
991,685

 
26
%
 
$
913,710

 
26
%
 
9
 %
Support and maintenance
785,039

 
21
%
 
761,165

 
22
%
 
3
 %
Services
1,978,444

 
52
%
 
1,800,309

 
51
%
 
10
 %
Reimbursed travel
73,319

 
2
%
 
63,470

 
2
%
 
16
 %
 
 
 
 
 
 
 
 
 
 
Total revenues
3,828,487

 
100
%
 
3,538,654

 
100
%
 
8
 %
 
 
 
 
 
 
 
 
 
 
Costs of revenue
 
 
 
 
 
 
 
 
 
Costs of revenue
624,960

 
16
%
 
564,119

 
16
%
 
11
 %
 
 
 
 
 
 
 
 
 
 
Total margin
3,203,527

 
84
%
 
2,974,535

 
84
%
 
8
 %
 
 
 
 
 
 
 
 
 
 
Operating expenses
 
 
 
 
 
 
 
 
 
Sales and client service
1,688,208

 
44
%
 
1,534,763

 
43
%
 
10
 %
Software development
442,570

 
12
%
 
405,451

 
11
%
 
9
 %
General and administrative
263,203

 
7
%
 
267,232

 
8
%
 
(2
)%
Amortization of acquisition-related intangibles
68,126

 
2
%
 
68,104

 
2
%
 
 %
 
 
 
 
 
 
 
 
 
 
Total operating expenses
2,462,107

 
64
%
 
2,275,550

 
64
%
 
8
 %
 
 
 
 
 
 
 
 
 
 
Total costs and expenses
3,087,067

 
81
%
 
2,839,669

 
80
%
 
9
 %
 
 
 
 
 
 
 
 
 
 
Operating earnings
741,420

 
19
%
 
698,985

 
20
%
 
6
 %
 
 
 
 
 
 
 
 
 
 
Other income, net
4,054

 
 
 
3,734

 
 
 
 
Income taxes
(215,154
)
 
 
 
(215,926
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net earnings
$
530,320

 
 
 
$
486,793

 
 
 
9
 %

23

Table of Contents

Revenues
Revenues increased 8% to $3.8 billion in the first nine months of 2017 , as compared to $3.5 billion in the same period of 2016 .
 
System sales increased 9% to $992 million in the first nine months of 2017 , from $914 million in the same period of 2016 . The increase in system sales was primarily driven by increases in licensed software and subscriptions of $51 million and $28 million, respectively.
Support and maintenance revenues increased 3% to $785 million in the first nine months of 2017 , from $761 million in the same period of 2016 . This increase was primarily attributable to continued success selling Cerner Millennium applications and implementing them at client sites.
Services revenue increased 10% to $2.0 billion in the first nine months of 2017 , from $1.8 billion in the same period of 2016 . This increase was driven by a $124 million increase in professional services due to growth in implementation and consulting activities, and growth in managed services of $54 million as a result of continued demand for our hosting services.

Costs of Revenue
Costs of revenue as a percent of total revenues were 16% in the first nine months of both 2017 and 2016 .

Operating Expenses
Total operating expenses increased 8% to $2.5 billion in the first nine months of 2017 , as compared to $2.3 billion in the same period of 2016 .
 
Sales and client service expenses as a percent of total revenues were 44% in the first nine months of 2017 , compared to 43% in the same period of 2016 . These expenses increased 10% to $1.7 billion in the first nine months of 2017 , from $1.5 billion in the same period of 2016 . The growth in sales and client service expenses reflects hiring of services personnel to support the strong growth in services revenue.
Software development expenses as a percent of total revenues were 12% in the first nine months of 2017 , compared to 11% in the same period of 2016 . Expenditures for software development include ongoing development and enhancement of the Cerner Millennium and HealtheIntent platforms, with a focus on supporting key initiatives to enhance physician experience, revenue cycle and population health solutions. A summary of our total software development expense in the first nine months of 2017 and 2016 is as follows:
 
Nine Months Ended
(In thousands)
2017
 
2016
 
 
 
 
Software development costs
$
526,257

 
$
531,825

Capitalized software costs
(207,910
)
 
(226,640
)
Capitalized costs related to share-based payments
(2,123
)
 
(2,163
)
Amortization of capitalized software costs
126,346

 
102,429

 
 
 
 
Total software development expense
$
442,570

 
$
405,451

 
General and administrative expenses as a percent of total revenues were 7% in the first nine months of 2017 , compared to 8% in the same period of 2016 . These expenses decreased 2% to $263 million in the first nine months of 2017 , from $267 million in the same period of 2016 . The decrease in general and administrative expenses includes lower expense for share-based payments, driven by stock option awards forfeited by our former CEO upon his passing in July 2017.

Amortization of acquisition-related intangibles as a percent of total revenues were 2% in the first nine months of both 2017 and 2016 . These expenses remained flat at $68 million in the first nine months of both 2017 and 2016 .


24

Table of Contents

Non-Operating Items
 
Other income, net was $4 million in the first nine months of both 2017 and 2016 .

Our effective tax rate was 28.9% for the first nine months of 2017 and 30.7% in the same period of 2016 . The decrease in the effective tax rate in 2017 is primarily a result of the inclusion of net excess tax benefits as discrete items within the tax provision, upon our adoption of ASU 2016-09 in the first quarter of 2017 . Refer to Note (1) of the notes to condensed consolidated financial statements for further discussion regarding our adoption of ASU 2016-09 and its impact on our condensed consolidated financial statements.

Operations by Segment

The following table presents a summary of our operating segment information for the first nine months of 2017 and 2016 :
(In thousands)
2017
 
% of Revenue
 
2016
 
% of Revenue
 
% Change  
 
 
 
 
 
 
 
 
 
 
Domestic Segment
 
 
 
 
 
 
 
 
 
Revenues
$
3,421,429

 
100%
 
$
3,132,566

 
100%
 
9%
 
 
 
 
 
 
 
 
 
 
Costs of revenue
549,895

 
16%
 
488,404

 
16%
 
13%
Operating expenses
1,474,591

 
43%
 
1,304,731

 
42%
 
13%
Total costs and expenses
2,024,486

 
59%
 
1,793,135

 
57%
 
13%
 
 
 
 
 
 
 
 
 
 
Domestic operating earnings
1,396,943

 
41%

1,339,431

 
43%
 
4%
 
 
 
 
 
 
 
 
 
 
Global Segment
 
 
 
 
 
 
 
 
 
Revenues
407,058

 
100%
 
406,088

 
100%
 
—%
 
 
 
 
 
 
 
 
 
 
Costs of revenue
75,065

 
18%
 
75,715

 
19%
 
(1)%
Operating expenses
197,333

 
48%
 
183,824

 
45%
 
7%
Total costs and expenses
272,398

 
67%
 
259,539

 
64%
 
5%
 
 
 
 
 
 
 
 
 
 
Global operating earnings
134,660

 
33%
 
146,549

 
36%
 
(8)%
 
 
 
 
 
 
 
 
 
 
Other, net
(790,183
)
 
 
 
(786,995
)
 
 
 
—%
 
 
 
 
 
 
 
 
 
 
Consolidated operating earnings
$
741,420

 
 
 
$
698,985

 
 
 
6%
Domestic Segment
Revenues increased 9% to $3.4 billion in the first nine months of 2017 , from $3.1 billion in the same period of 2016 . This increase was primarily driven by growth in services revenue.
Costs of revenue as a percent of revenues were 16% in the first nine months of both 2017 and 2016 .
Operating expenses as a percent of revenues were 43% in the first nine months of 2017 , compared to 42% in the same period of 2016 . The increase as a percent of revenues reflects a higher mix of services in 2017 that was driven by services revenue growth.

Global Segment
Revenues were flat at $407 million in the first nine months of 2017 , and $406 million in the same period of 2016 .
Costs of revenue were flat at $75 million in the first nine months of 2017 , and $76 million in the same period of 2016 .
Operating expenses as a percent of revenues were 48% in the first nine months of 2017 , compared to 45% in the same period in 2016 . The increase as a percent of revenues is primarily due to an increase in non-personnel expenses.

Other, net
These expenses remained relatively flat at $790 million in the first nine months of 2017 and $787 million in the same period of 2016 .

25

Table of Contents

Liquidity and Capital Resources
Our liquidity is influenced by many factors, including the amount and timing of our revenues, our cash collections from our clients and the amount we invest in software development, acquisitions, capital expenditures, and in recent years, our share repurchase programs.
Our principal sources of liquidity are our cash, cash equivalents, which primarily consist of money market funds, commercial paper and time deposits with original maturities of less than 90 days, and short-term investments. At September 30, 2017 , we had cash and cash equivalents of $573 million and short-term investments of $279 million , as compared to cash and cash equivalents of $171 million and short-term investments of $186 million at December 31, 2016 .
The non-U.S. subsidiaries for which we have elected to indefinitely reinvest earnings outside of the U.S. held approximately 24% of our aggregate cash, cash equivalents, and short-term investments at September 30, 2017 . As part of our current business strategy, we plan to indefinitely reinvest the earnings of these foreign operations; however, should the earnings of these foreign operations be repatriated, we would accrue and pay tax on such earnings, which may be material.

We maintain a $100 million multi-year revolving credit facility, which expires in October 2020. The facility provides an unsecured revolving line of credit for working capital purposes, along with a letter of credit facility. We have the ability to increase the maximum capacity to $200 million at any time during the facility's term, subject to lender participation. As of September 30, 2017 , we had no outstanding borrowings under this facility; however, we had $42 million of outstanding letters of credit, which reduced our available borrowing capacity to $58 million .

We believe that our present cash position, together with cash generated from operations, short-term investments and, if necessary, our available line of credit, will be sufficient to meet anticipated cash requirements for the next 12 months.
The following table summarizes our cash flows in the first nine months of 2017 and 2016 :
 
Nine Months Ended
(In thousands)
2017
 
2016
 
 
 
 
Cash flows from operating activities
$
958,765

 
$
907,698

Cash flows from investing activities
(593,689
)
 
(695,595
)
Cash flows from financing activities
27,639

 
(179,785
)
Effect of exchange rate changes on cash
9,478

 
(2,943
)
Total change in cash and cash equivalents
402,193

 
29,375

 
 
 
 
Cash and cash equivalents at beginning of period
170,861

 
402,122

 
 
 
 
Cash and cash equivalents at end of period
$
573,054

 
$
431,497

 
 
 
 
Free cash flow (non-GAAP)
$
486,360

 
$
351,034


Refer to Note (1) of the notes to condensed consolidated financial statements for discussion regarding our adoption of ASU 2016-09 in the first quarter of 2017, which impacted the classification of certain items within our condensed consolidated statements of cash flows.

Cash from Operating Activities
 
Nine Months Ended
(In thousands)
2017
 
2016
 
 
 
 
Cash collections from clients
$
4,060,904

 
$
3,796,652

Cash paid to employees and suppliers and other
(2,917,105
)
 
(2,707,928
)
Cash paid for interest
(17,175
)
 
(17,397
)
Cash paid for taxes, net of refunds
(167,859
)
 
(163,629
)
 
 
 
 
Total cash from operations
$
958,765

 
$
907,698

Cash flow from operations increased $51 million in the first nine months of 2017 when compared to the same period of 2016 due primarily to an increase in cash impacting earnings, partially offset by an increase in cash used to fund working capital

26

Table of Contents

requirements. During the first nine months of 2017 and 2016 , we received total client cash collections of $4.1 billion and $3.8 billion , respectively. Days sales outstanding was 73 days in the third quarter of 2017 , compared to 73 days in the second quarter of 2017 and 76 days in the third quarter of 2016 . Revenues provided under support and maintenance agreements represent recurring cash flows. We expect these revenues to continue to grow as the base of installed systems grows.
Cash from Investing Activities
 
Nine Months Ended
(In thousands)
2017
 
2016
 
 
 
 
Capital purchases
$
(262,372
)
 
$
(327,861
)
Capitalized software development costs
(210,033
)
 
(228,803
)
Purchases of investments, net of sales and maturities
(99,098
)
 
(125,709
)
Purchases of other intangibles
(22,186
)
 
(13,222
)
 
 
 
 
Total cash flows from investing activities
$
(593,689
)
 
$
(695,595
)
Cash flows from investing activities consist primarily of capital spending and short-term investment activities.

Our capital spending in the first nine months of 2017 was driven by capitalized equipment purchases primarily to support growth in our managed services business, investments in a cloud infrastructure to support cloud-based solutions, building and improvement purchases to support our facilities requirements and capitalized spending to support our ongoing software development initiatives. Capital purchases in 2017 are expected to remain lower than 2016 levels, as we completed the first two phases of construction on our Innovations Campus (office space development located in Kansas City, Missouri) in January 2017.

Short-term investment activity consists of the investment of cash generated by our business in excess of what is necessary to fund operations. We expect to continue short-term investment activity over the remainder of 2017 , as we expect strong levels of cash flow.

Cash from Financing Activities
 
Nine Months Ended
(In thousands)
2017
 
2016
 
 
 
 
Cash from option exercises (net of taxes paid in connection with shares surrendered by associates)
$
53,699

 
$
22,364

Treasury stock purchases
(23,389
)
 
(200,075
)
Contingent consideration payments for acquisition of businesses
(2,671
)
 
(2,074
)
 
 
 
 
Total cash flows from financing activities
$
27,639

 
$
(179,785
)
Cash inflows from stock option exercises are dependent on a number of factors, including the price of our common stock, grant activity under our stock option and equity plans, and overall market volatility. We expect net cash inflows from stock option exercises to continue throughout 2017 based on the number of exercisable options as of September 30, 2017 and our current stock price.

During the first nine months of 2017 , we repurchased 0.4 million shares of our common stock under our share repurchase programs for total consideration of $23 million. As of September 30, 2017 , $77 million remains available for repurchase under the program authorized by our Board of Directors in November 2016, and an additional $500 million remains available for repurchase under the program authorized in May 2017. We may continue to repurchase shares under these programs in 2017 , which will be dependent on a number of factors, including the price of our common stock. Although we may continue to repurchase shares, there is no assurance that we will repurchase up to the full amount remaining under the programs.

During the first nine months of 2016 , we repurchased 3.7 million shares of common stock under our share repurchase programs for total consideration of $200 million.


27

Table of Contents

Free Cash Flow (Non-GAAP)
 
Three Months Ended
 
Nine Months Ended
(In thousands)
2017
 
2016
 
2017
 
2016
 
 
 
 
 
 
 
 
Cash flows from operating activities (GAAP)
$
362,937

 
$
311,064

 
$
958,765

 
$
907,698

Capital purchases
(73,000
)
 
(110,266
)
 
(262,372
)
 
(327,861
)
Capitalized software development costs
(67,067
)
 
(73,628
)
 
(210,033
)
 
(228,803
)
 
 
 
 
 
 
 
 
Free cash flow (non-GAAP)
$
222,870

 
$
127,170

 
$
486,360

 
$
351,034


Free cash flow increased $135 million in the first nine months of 2017 compared to the same period in 2016 . This increase is primarily due to increased operating cash flow, along with reduced capital purchases as discussed above. Free cash flow is a non-GAAP financial measure used by management along with GAAP results to analyze our earnings quality and overall cash generation of the business. We define free cash flow as cash flows from operations reduced by capital purchases and capitalized software development costs. The table above sets forth a reconciliation of free cash flow to cash flows from operating activities, which we believe to be the GAAP financial measure most directly comparable to free cash flow. The presentation of free cash flow is not meant to be considered in isolation, nor as a substitute for, or superior to, GAAP results, and investors should be aware that non-GAAP measures have inherent limitations and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Free cash flow may also be different from similar non-GAAP financial measures used by other companies and may not be comparable to similarly titled captions of other companies due to potential inconsistencies in the method of calculation. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational and economic performance, because free cash flow takes into account certain capital expenditures necessary to operate our business.


28

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

No material changes.

Item 4. Controls and Procedures

a)
Evaluation of Disclosure Controls and Procedures.

The Company's Interim Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this quarterly report on Form 10-Q (the "Evaluation Date"). They have concluded that, as of the Evaluation Date, these disclosure controls and procedures were effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities and would be disclosed on a timely basis. The CEO and CFO have concluded that the Company’s disclosure controls and procedures are designed, and are effective, to give reasonable assurance that the information required to be disclosed by the Company in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the rules and forms of the SEC. They have also concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act are accumulated and communicated to the Company’s management to allow timely decisions regarding required disclosure.

b)
Changes in Internal Control over Financial Reporting.

During the fiscal quarter ended September 30, 2017, progress continued on a plan that calls for modifications and enhancements to the Company’s internal controls over financial reporting in relation to our upcoming adoption of the new revenue recognition standard effective in the first quarter of 2018. Such plan resulted in changes to certain process and procedures during the quarter. Specifically, we implemented/modified internal controls to address:

Monitoring of the adoption process
The gathering of information and evaluation of analysis used in the development of disclosures required prior to the new standard’s effective date

As we continue the implementation process, we expect that there will be additional changes in internal controls over financial reporting.

During the fiscal quarter ended September 30, 2017, we implemented a new human resources administration and payroll system. Certain internal controls were modified in connection with the implementation of this new system.

There were no other changes in the Company’s internal controls over financial reporting during the fiscal quarter ended September 30, 2017 , that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

c)
Limitations on Controls.

The Company’s management, including its CEO and CFO, has concluded that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at that reasonable assurance level. However, the Company’s management can provide no assurance that our disclosure controls and procedures or our internal control over financial reporting can prevent all errors and all fraud under all circumstances. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

29

Table of Contents

Part II. Other Information

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c) Issuer Purchases of Equity Securities

The table below provides information with respect to Common Stock purchases by the Company during the third fiscal quarter of 2017 .
 
 
Total Number of Shares Purchased (a)
 
Average Price Paid per Share
 
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)
 
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (b)
Period
 
 
 
 
July 2, 2017 - July 29, 2017
 

 
$

 

 
$
600,000,000

July 30, 2017 - August 26, 2017
 
285,726

 
64.25

 
285,726

 
581,642,586

August 27, 2017 - September 30, 2017
 
77,556

 
65.00

 
77,300

 
576,618,633

 
 
 
 
 
 
 
 
 
Total
 
363,282

 
$
64.41

 
363,026

 
 
(a)
Of the 363,282 shares of common stock, par value $0.01 per share, presented in the table above, 256 were originally granted to employees as restricted stock pursuant to our 2011 Omnibus Equity Incentive Plan (the "Omnibus Plan"). The Omnibus Plan allows for the withholding of shares to satisfy the minimum tax obligations due upon the vesting of restricted stock. Pursuant to the Omnibus Plan, the 256 shares reflected above were relinquished by employees in exchange for our agreement to pay U.S. federal and state withholding obligations resulting from the vesting of the Company’s restricted stock.

(b)
During the nine months ended September 30, 2017 , the Company repurchased 0.4 million shares of our common stock under our share repurchase programs for consideration of $23 million, excluding transaction costs, pursuant to Rule 10b5-1 plans.

As announced on November 14, 2016, our Board of Directors authorized a share repurchase program for an aggregate purchase of up to $500 million of our common stock, excluding transaction costs. As of September 30, 2017, $77 million remained available for repurchase under this plan. No time limit has been set for completion of this program.

As announced on May 25, 2017, our Board of Directors authorized a separate share repurchase program for an aggregate purchase of up to $500 million of our common stock, excluding transaction costs. As of September 30, 2017, $500 million remained available for repurchase under this plan. No time limit has been set for completion of this program.
    


30

Table of Contents

Item 6. Exhibits
(a)
 
Exhibits
 
 
 
10.1
 
 
 
 
10.2
 
 
 
 
10.3
 
 
 
 
10.4
 

 
 
 
10.5
 
 
 
 
10.6
 
 
 
 
10.7
 
 
 
 
10.8
 
 
 
 
10.9
 
 
 
 
10.10
 
 
 
 
10.11
 
 
 
 
31.1
 
 
 
 
31.2
 
 
 
 
32.1
 
 
 
 
32.2
 
 
 
 
101.INS
 
XBRL Instance Document
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document

31

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
 
CERNER CORPORATION
 
 
Registrant
 
 
 
 
Date: October 27, 2017
 
By:
/s/ Marc G. Naughton
 
 
  
Marc G. Naughton
 
 
  
Executive Vice President and Chief
 
 
  
Financial Officer (duly authorized
 
 
 
officer and principal financial officer)




Exhibit 10.1

Enhanced Severance Pay Plan

As Amended and Restated Effective October 1, 2017
Section 1. Introduction
a. Purpose
Cerner Corporation and its United States-based wholly-owned subsidiaries ("Cerner") value the contributions of their Associates and take measures to create and maintain a productive and fulfilling work environment. However, Cerner recognizes that business needs, an Associate's work performance or other reasons may require termination of employment. At any point during an Associate's employment, Cerner may choose to terminate the employment relationship.
Because employment with Cerner is at-will, Cerner has no obligation to compensate any Associate upon termination from his or her employment other than as may be provided in that Associate's Employment Agreement or as specifically set forth in this Enhanced Severance Pay Plan ("Plan"). Cerner values its Associates and is interested in helping to mitigate the financial hardship caused by business conditions or other factors necessitating a termination.
b. Overview
Generally, this Plan provides enhanced Severance Benefits to Associates upon either a (i) "Non-CIC Severance" or (ii) "CIC Severance", as such terms are defined herein. Cerner expressly reserves the right to amend or terminate this Plan, or the benefits provided hereunder, at any time; provided, however, that no such amendment or termination shall occur with respect to the CIC Severance Benefits after the occurrence of a Change in Control.
c. Summary Plan Description
This Plan document also constitutes the Summary Plan Description for the Plan.
Section 2. Definitions
Certain capitalized terms used herein are defined parenthetically throughout this Plan and/or defined in this Section 2.
a. Associate
“Associate” means an employee of Cerner.
b. Beneficial Ownership
"Beneficial Ownership", "Beneficial Owner" or "Beneficially Own" shall have the same meaning as such terms are used in Rule 13d-3 of the Exchange Act.
c. Board
"Board" means the Board of Directors of Cerner Corporation.
d. Cause
"Cause" means an Eligible Associate's (i) material breach of his/her Employment Agreement or material neglect of his/her duties and responsibilities thereunder, (ii) fraud against Cerner, (iii) misappropriation of Cerner's assets, (iv) embezzlement from Cerner, (v) theft from Cerner, (vi) acts resulting in the arrest and indictment for a crime involving drug abuse, violence, dishonesty or theft or (vii) act or failure to take any action that results in a violation of the Sarbanes-Oxley Act of 2002, or any related statutes, laws or regulations.
e. Change in Control
"Change in Control" means:
1.
The acquisition by any "Person" (as the term "person" is used for purposes of Section 13(d) or 14(d) of the Exchange Act) of Beneficial Ownership of thirty-five percent (35%) or more of either: (A) the then outstanding shares of common stock of Cerner Corporation (the "Outstanding Cerner Common Stock"), or (B) the combined voting power of the then outstanding voting securities of Cerner Corporation entitled to vote generally in the election of the Board's directors (the "Outstanding Cerner Voting Securities"); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (X) any acquisition directly from Cerner, (Y) any acquisition by Cerner or (Z) any acquisition by any Associate benefit





plan (or related trust) sponsored or maintained by Cerner Corporation or any corporation controlled by Cerner; or
2.
Individuals who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a Board director subsequent to the date hereof whose appointment or election, or nomination for election by Cerner's shareholders, was approved by a vote of at least a majority of the Board directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of Board directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
3.
Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of Cerner (a "Business Combination"), in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the Beneficial Owners, respectively, of the Outstanding Cerner Common Stock and Outstanding Cerner Voting Securities immediately prior to such Business Combination Beneficially Own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of Cerner Corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns Cerner or all or substantially all of Cerner's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Cerner Common Stock and Outstanding Cerner Voting Securities, as the case may be, (B) no Person (excluding any Associate benefit plan (or related trust) of Cerner or such corporation resulting from such Business Combination) Beneficially Owns, directly or indirectly, 35% or more of, respectively, the then outstanding shares of common stock of Cerner Corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination and (C) at least a majority of the members of the Board resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or
4.
Approval by the shareholders of Cerner Corporation of a complete liquidation or dissolution of Cerner.
f. CIC Protected Period
"CIC Protected Period" means the period beginning on the effective date of a Change in Control and ending on the one-year anniversary of such effective date.
g. CIC Severance
"CIC Severance" means, at any time during the CIC Protected Period, an Eligible Associate's termination of employment with Cerner (or its successor), that also qualifies as a separation from service under Section 409A of the Code, due to (i) Cerner's (or its successor’s) termination without Cause of the Eligible Associate's employment, or (ii) the Eligible Associate's resignation for Good Reason.
h. CIC Severance Benefits
"CIC Severance Benefits" means those severance benefits set forth in Section 4(b) that, provided an Eligible Associate is entitled to receive such benefits in accordance with Section 3, the Eligible Associate receives following a CIC Severance.
i. CIC Week of Severance Pay
A "CIC Week of Severance Pay" means an Eligible Associate's: (i) regular weekly base rate of pay in effect on the effective date of a CIC Severance (prior to any reductions taken for payroll taxes, income tax withholdings, elective deferrals made to or in connection with Cerner's Associate benefit plans or Executive Deferred Compensation Plan, and excluding any overtime, bonuses, commissions, premium pay, benefits, expense reimbursements, etc.), plus (ii) the average annual cash bonus the Associate had received from Cerner during the three (3) years preceding the CIC Severance (prior to any reductions taken for payroll taxes, income tax withholdings, elective deferrals made to or in connection with Cerner's Associate benefit plans or Executive Deferred Compensation Plan, and excluding any overtime, bonuses, commissions, premium pay, benefits, expense reimbursements, etc.), divided by 52 weeks. For example, a CIC Week of Severance Pay for an Eligible Associate whose: (i) annual base salary (excluding the pay and benefits listed above) is $52,000, and (ii) whose average annual cash bonus received during the three (3) years preceding the CIC Severance is $15,600, would be $1,000 ($52,000/52 weeks) plus $300 ($15,600/52 weeks), equaling a CIC Week of Severance Pay of $1,300. Cerner’s cash bonus plan currently pays a bonus, if earned, following each





fiscal quarter of Cerner. When calculating the average annual cash bonus, the actual cash bonus paid to the Associate (or earned but not yet paid for the most recent full fiscal quarter preceding the CIC Severance) for the twelve (12) consecutive full Cerner fiscal quarters immediately preceding the CIC Severance shall be included in the calculation of the Associate’s average annual cash bonus for the three (3) years preceding the CIC Severance. If the Associate has not been employed by Cerner for twelve (12) consecutive full Cerner fiscal quarters immediately prior to the CIC Severance, the average annual cash bonus received by such Associate shall be calculated based on the number of consecutive full fiscal quarters the Associate has been employed by Cerner immediately prior to the CIC Severance and adjusted to equal a yearly average. For avoidance of all doubt, the calculation of average annual cash bonus shall not include any sales commissions or similar payments received by an Associate based on individual sales or contracts signed with Cerner clients.
j. COBRA
"COBRA" means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
k. Code
"Code" means the Internal Revenue Code of 1986, as amended.
l. Eligible Associate
"Eligible Associate" means an individual who: (i) is a permanent, full-time Associate on the U.S. payroll of Cerner, as determined by Cerner's employment records; and (ii) has entered into an Employment Agreement. The determination of whether an Associate is an Eligible Associate shall be made by the Plan Administrator, in its sole discretion, and such determination shall be binding and conclusive on all persons. In no event shall part-time Associates, interns or independent contractors be Eligible Associates.
m. Employment Agreement
"Employment Agreement" means an Eligible Associate's then current Cerner Associate Employment Agreement, as amended, supplemented or otherwise modified, with Cerner.
n. Exchange Act
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
o. Excess Severance Benefit
"Excess Severance Benefits" means any Severance Benefits that exceed the limit provided in Treas. Reg. Section 1.409A-1(b)(9)(iii).
p. Good Reason
"Good Reason" means, without an Eligible Associate's express written consent: (i) a material adverse change in the Eligible Associate's authority, duties or job responsibilities (except for such subordination in duties and job responsibilities as may normally be required due to Cerner's change from an independent business entity to a subsidiary or division of another corporate entity); or (ii) a reduction of 5% or more to an Eligible Associate's annual salary and cash bonus opportunity in effect prior to the Change in Control; provided, however, the Eligible Associate must provide notice to Cerner (or its successors) within 30 days after the adverse change or reduction and must give Cerner (or its successors) at least 30 days to remedy the event or condition. In no event will an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Cerner (or its successors) constitute Good Reason.
q. Non-CIC Severance
"Non-CIC Severance" means at any time, other than during a CIC Protected Period, an Eligible Associate's termination of employment with Cerner, that also qualifies as a separation from service under Section 409A of the Code, by Cerner, other than for Cause, due to reorganization, restructuring, unsatisfactory work performance (other than where such unsatisfactory work performance is deliberate), or for other reasons as determined by the Plan Administrator in its sole discretion to constitute a Non-CIC Severance. Without limitation, the following events and reasons shall not constitute a Non-CIC Severance:
1.
death;
2.
disability;
3.
voluntary resignation (regardless of the circumstances surrounding the Eligible Associate's decision to resign);
4.
retirement;
5.
discharge by Cerner for any other work related reason other than redundancy or unsatisfactory work performance (including, without limitation, absenteeism, misconduct, refusal to transfer to an equivalent





position that does not require relocation, failure to return to work after an approved leave of absence, insubordination, violation of Cerner's rules or policies, dishonesty, deliberate unsatisfactory performance, etc.);
6.
CIC Severance; or
7.
termination for Cause.
r. Non-CIC Severance Benefits
"Non-CIC Severance Benefits" means those severance benefits set forth in Section 4(a) that, provided an Eligible Associate is entitled to receive such benefits in accordance with Section 3, the Eligible Associate receives following a Non-CIC Severance.
s. Plan Administrator
"Plan Administrator" means the person or entity specified as such in Section 7.
t. Role Level
"Role Level" means an Eligible Associate's designated category of employment as specified by Cerner's current employment classification hierarchy. In the event Cerner changes its hierarchy structure, the Role Levels specified in this Plan shall refer to the equivalent Role Level under any new classification scheme.
u. Severance Benefits
“Severance Benefits” means either CIC Severance Benefits or Non-CIC Severance Benefits.
v. Specified Associate
"Specified Associate" means an Associate that would be a "specified employee" as defined in Section 409A(a)(2)(B)(i) of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder.
w. Week of Severance Pay
"Week of Severance Pay" means an Eligible Associate's regular weekly base rate of pay in effect on the effective date of a Non-CIC Severance (prior to any reductions taken for payroll taxes, income tax withholdings, elective deferrals made to or in connection with Cerner's Associate benefit plans or Executive Deferred Compensation Plan, and excluding any overtime, bonuses, commissions, premium pay, benefits, expense reimbursements, etc.). For example, a Week of Severance Pay for an Eligible Associate whose annual base salary as of the Non-CIC Severance (excluding the pay and benefits listed above) is $52,000, would be $1,000 ($52,000/52 weeks).
x. Year of Service
"Year of Service" means, with respect to an Eligible Associate, each period of twelve (12) consecutive months of full-time employment by Eligible Associate with Cerner beginning with the Associate's full-time employment commencement date with Cerner and ending with the day preceding the anniversary of such date in the next and all succeeding years. No partial Years of Service shall be credited under this Plan nor will prorated Severance Benefits be paid for any fractional Year of Service.
Section 3. Entitlement for Severance Benefits
a. Entitlement
Subject to the exceptions set forth below in Section 3(b), an Eligible Associate shall be entitled to receive either the Non-CIC Severance Benefits or the CIC Severance Benefits described below in Section 4, upon experiencing a Non-CIC Severance or CIC Severance, respectively, and provided that the following conditions are satisfied:
1.
The Eligible Associate's termination of employment with Cerner must have constituted either a CIC Severance or Non-CIC Severance. In no event shall an Associate’s leave during one of Cerner’s recognized leave programs constitute a termination of employment event under this Plan,
2.
Following or in connection with the Eligible Associate's termination of employment, the Eligible Associate must comply with all transition assistance requests of Cerner, to Cerner's satisfaction, such as aiding in the location of files and documents, returning all Cerner property and repaying any amounts owed Cerner, and
3.
With respect to and in connection with a Non-CIC Severance only, the Eligible Associate has executed and delivered to Cerner (and not revoked by the end of any applicable revocation period) a Severance and Release Agreement with Cerner, such agreement providing for an irrevocable and complete release of all present and future claims by the Eligible Associate, within twenty-one (21) days or forty-five (45) days, whichever period is required under applicable law. The end of any applicable revocation period, which in no event is to exceed seven (7) days (unless otherwise required by applicable law), is referred to in this Plan as the “Release Period Deadline.”





b. Exceptions to Severance Entitlement
An Eligible Associate will not receive Severance Benefits under this Plan in the following circumstances, as determined in the Plan Administrator's sole discretion:
1.
Any of (a) the Eligible Associate's Employment Agreement (or amendments or supplement thereto), (b) another broad-based Cerner severance plan or policy, or (c) any other agreement with Cerner providing for severance payments upon the Associate’s involuntary termination from Cerner, provide that none of the benefits provided under this Plan shall apply to the Associate or such agreement, plan or policy provides that it shall apply to the Associate.
2.
The Associate breaches the terms and conditions of his/her Employment Agreement (including, without limitation, violating the non-competition provisions thereof).
3.
With respect to Non-CIC Severance Benefits only: (a) the Eligible Associate's employment termination is in connection with the sale, divesture or other disposition of the stock or assets of any subsidiary, division or other operating unit of Cerner or any of its subsidiaries ("Operating Unit") (or part thereof) which does not constitute a Change in Control (a "Transaction"), and the Eligible Associate is offered continued employment, or continues in employment, with the divested Operating Unit (or part thereof) or the purchaser of the stock or assets of the Operating Unit (or part thereof), or one of such purchaser's affiliates (the "Post-Transaction Employer"), as the case may be, on terms and conditions that would not constitute Good Reason, and (b) Cerner obtains an agreement from the Post-Transaction Employer, enforceable by the Eligible Associate, to provide (or Cerner agrees to provide) severance pay, if the Eligible Associate accepts the offered employment or continues in employment with the Post-Transaction Employer or its affiliates following the Transaction, at least equal to the severance pay set forth in Section 4(a) payable upon a Non-CIC Severance termination of the Eligible Associate's employment with the Post-Transaction Employer or its affiliates within the six (6) month period following the Transaction. For purposes of this Section 3(b)(3), the term "Good Reason" shall have the meaning ascribed to it in this Plan, but the term "Cerner" as it is used in such definition shall be deemed to refer to the Post-Transaction Employer employing the Eligible Associate after the Transaction. For avoidance of doubt, in the circumstances described in the first sentence of this Section 3(b)(3), the Eligible Associate shall not be entitled to receive Non-CIC Severance Benefits under Section 4(a) whether or not the Eligible Associate accepts the offered employment or continues in employment. Except as to separate severance benefits Cerner may itself expressly agree to in writing to provide in connection with a Transaction (as contemplated by subpart (b) of the first sentence of this Section 3(b)(3)), the provisions of this Section 3(b)(3) do not create any entitlement to Severance Benefits from Cerner in any circumstances whatsoever and are to be construed solely as a limitation on such entitlement in the circumstances herein set forth.
Section 4. Severance Benefits
a. Non-CIC Severance Benefits
If the termination of an Eligible Associate's employment constitutes a Non-CIC Severance, Cerner shall pay the Eligible Associate an amount of severance pay based on the Eligible Associate's Role Level and Years of Service with Cerner as of the effective date of such termination. The amount of such severance pay shall be equal to: (i) a Week of Severance Pay for such Eligible Associate multiplied by (ii) that number set forth in a severance matrix, adopted periodically by management, outlining the severance benefits to which Eligible Associates shall be entitled (“Severance Matrix”). The Severance Matrix shall be attached hereto as Exhibit A, and dated to reflect the most recent adoption date by management.
b. CIC Severance Benefits
If the termination of an Eligible Associate's employment constitutes a CIC Severance, Cerner shall pay the Eligible Associate an amount of severance pay based on the Eligible Associate's Role Level and Years of Service with Cerner as of the effective date of such termination. The amount of such CIC Severance Benefits shall be equal to: (i) a CIC Week of Severance Pay for such Eligible Associate multiplied by (ii) that number set forth in the current Severance Matrix, multiplied by 1.5.
c. Form of Payment
1.
Before any Change in Control and except with respect to Excess Severance Benefits, and following receipt of the signed Severance and Release Agreement document and the expiration of the applicable Release Period Deadline, all Non-CIC Severance Benefits shall be paid in a lump sum or, if the Plan Administrator elects, as salary continuation (without interest) on regularly scheduled paydays of Cerner for the applicable severance period or some other method, but in no event shall payments continue beyond the last day of the twenty-fourth (24th) month following the month in which the Non-CIC Severance occurs.





2.
Before a Change in Control, all Non-CIC Severance Benefits which are Excess Severance Benefits shall be paid in a lump sum as soon as practicable within 75 days of the Non-CIC Severance.
3.
After a Change in Control and subject to the immediately following sentence, all Severance Benefits shall be paid in lump sum and (A) if the Severance Benefits are on account of a Non-CIC Severance, such that the payment of such benefits is subject to the Severance and Release Agreement requirements described above in Section 3(a)(3), such Non-CIC Severance Benefits shall be paid on the last day of the Release Period Deadline, and (B) if the Severance Benefits are on account of a CIC Severance, such that the payment of such benefits is not subject to the Severance and Release Agreement requirements described above in Section 3(a)(3), such CIC Severance Benefits shall be paid within seventy-five (75) days of the CIC Severance. Notwithstanding the immediately preceding sentence, if the Associate receiving any Severance Payment subject to this Section 4(c)(3) is a Specified Associate, then the payment of any Severance Benefits shall be delayed until and paid on the first day of the seventh month following the CIC or Non-CIC Severance.
4.
All Severance Benefit payments are subject to the offset provisions of Section 6(c) of the Plan.
d. Withholding
All Severance Benefits made under this Plan will be subject to applicable withholding for federal, state and local taxes. If any Eligible Associate is indebted to Cerner at his or her termination date, Cerner reserves the right to offset any Severance Benefits under this Plan by the amount of such indebtedness.
Section 5. Employment
a. No Modification of Associate Employment Agreements
This Plan shall not modify any terms of an Eligible Associate's Employment Agreement, including but not limited to the type of employment relationship, the Associate's obligations and continuing obligations set forth therein.
b. Limitation on Associate Rights
This Plan shall not give any Associate the right to be retained in the service of Cerner or interfere with or restrict the right of Cerner to terminate the employment of any Associate.
c. Changed Decisions
Cerner has the right to cancel or reschedule the effective date of an Eligible Associate's employment termination. An Eligible Associate will not be eligible for any Severance Benefits under this Plan if the Eligible Associate's employment termination is canceled by Cerner, or if the Eligible Associate is offered an opportunity to return to work or have his or her employment reinstated with Cerner.
Section 6. Relation to Other Benefits and Pay
a. COBRA
Associates and their dependents covered under one or more of Cerner's group health plans may be eligible for continuation coverage pursuant to the federal COBRA law. This Plan does not provide Associates or their dependents with any greater right to continuation coverage than what the federal COBRA law requires.
b. Other Benefit Plans
Eligibility, coverage and benefits under other Cerner benefit plans (e.g., any group life, disability, accidental death, retirement, stock plans, etc.) are governed by the terms of those respective plans. This Plan does not provide Associates or their beneficiaries and dependents with any greater eligibility, coverage or benefits than what such plans provide.
c. Offset of Benefits and Integration with Other Payments
Except as may otherwise be specifically provided for in an Associate's Employment Agreement or any other agreement with Cerner and subject to the immediately following sentence, the amount of any Severance Benefits paid under this Plan will be offset by any other severance-type payments an Eligible Associate may otherwise be entitled to receive from Cerner, including under an Employment Agreement or other agreement with Cerner that provides for payments upon the Associate’s involuntary termination from Cerner (with relating to a change in control or otherwise), pay-in-lieu of notice, severance pay, workers compensation wage replacement, disability pay, or similar benefits or pay under other benefit plans, severance programs, employment agreements, transaction documents or applicable laws, such as the WARN Act. Notwithstanding the foregoing, in no event shall the timing of any payment which is otherwise subject to Code section 409A be modified if such modification would result in a violation of Code section 409A and, in such event, all severance payments from Cerner shall be made in a manner, as determined by the Plan Administrator in its sole discretion, that would allow both this Plan and the other plan or agreement to operate in compliance with Code section 409A. In no event however shall this provision preclude an otherwise Eligible Associate from receiving any payments under a Cerner Performance Plan (CPP) or any pay for accrued, but unused, time off under Cerner’s separate





CPP or personal time off policy, as may be amended from time-to-time. CPP and pay for, but unused, time off, if any, shall be paid pursuant to the terms of those separate plans or policies.
d. Reemployment
If an Eligible Associate is reemployed by Cerner while Severance Benefits are still payable under the Plan, all such Severance Benefits will cease, except as otherwise specified by the Plan Administrator, in its sole discretion.
Section 7. Plan Administration
a. Plan Administrator
The Plan is administered by Cerner, which is the Plan Administrator under the Employee Retirement Income Security Act of 1974 ("ERISA"). It is the responsibility of the Plan Administrator to ensure that the Plan is administered in accordance with its terms. It is also the responsibility of the Plan Administrator to explain any rights and benefits that an Eligible Associate may have under the Plan and to answer any questions which an Eligible Associate may have. The Plan Administrator maintains all documents which comprise the Plan and annual filings, if any, which are prepared for the Plan. If you have any questions regarding the Plan, you should review these available documents. The Plan Administrator may, but is not required to, adopt rules and regulations of uniform applicability in its interpretation and implementation of the Plan. The Plan Administrator may require each Eligible Associate to submit, in such form as it shall deem reasonable and acceptable, proof of any information which the Plan Administrator finds necessary or desirable for the proper administration of the Plan.
b. Exclusive Discretion
The Plan Administrator has full and complete discretionary authority to determine eligibility for benefits under the Plan and to construe and interpret the terms of the Plan. In making any decision or resolving any disputes, the Plan Administrator shall have full and complete discretionary authority to (i) construe and interpret the provisions of the Plan and to determine the right of any person to any interest in or eligibility for any benefit under the Plan, and (ii) make any and all factual determinations necessary to determine the right of any person to any interest in or eligibility for any benefit under the Plan; and, no person shall be entitled to any benefit or interest under this Plan if the Plan Administrator decides in its discretion that there is no entitlement to that benefit or interest. Decisions of the Plan Administrator shall be final, binding and conclusive upon all parties.
Section 8. Amendment or Termination
Cerner, acting through its Chief Executive Officer, Chief Financial Officer, Chief Legal Officer or Chief People Officer, has the right, in its nonfiduciary capacity, to amend the Plan or to terminate it at any time, prospectively or retroactively, for any reason or no reason, without notice, including discontinuing or eliminating benefits; provided, however, that no such amendment or termination shall affect the right to any unpaid benefit of any Eligible Associate whose termination date has occurred prior to such amendment or termination of the Plan and provided further that no amendment or termination shall occur with respect to the CIC Severance Benefits after the occurrence of a Change in Control. Accordingly, no Associate has a “legally binding right” (as that term is used in Treasury Regulations § 1.409A-1(b)(1)) to any benefit or amount pursuant to this Plan until, if at all, the first to occur of an Associate’s Non-CIC Severance or a Change in Control and only then is the Associate entitled to those Severance Benefits, if any, as are provided for in the Plan at such time.
Section 9. Claims and Appeal Procedure
a. Initial Claim
If benefits under this Plan become due, the Plan Administrator will notify you as to the amount of benefits you are entitled to, the duration of such benefit, the time the benefit is to commence and other pertinent information concerning your benefit. If you have been denied a benefit under the Plan, or if you feel that the benefit which has been given to you is not accurate, you may file a claim with the Plan Administrator. If a claim for benefit is denied by the Plan Administrator, the Plan Administrator shall provide you with written or electronic notification of any adverse benefit determination within ninety (90) days after receipt of the claim unless special circumstances require an extension of time for processing the claim. If such an extension of time for processing is required, written or electronic notice indicating the special circumstances and the date by which a final decision is expected to be rendered shall be furnished to you. In no event shall the period of extension exceed one hundred eighty (180) days after receipt of the claim. The notice of denial of the claim shall set forth:
1.
The specific reason or reasons for the adverse determination;
2.
Reference to the specific plan provisions on which the determination is based;
3.
A description of any additional material or information necessary for you to perfect the claim, and an explanation of why such material or information is necessary; and





4.
A description of the Plan's review procedures and the time limits applicable to such procedures, including a statement of your right to bring a civil action under ERISA section 502(a) following an adverse benefit determination on review.
You (or your duly authorized representative) may review pertinent documents and submit issues and comments in writing to the Plan Administrator. If you fail to appeal such action to the Plan Administrator in writing within the prescribed period of time described in the next section, the Plan Administrator's adverse determination shall be final, binding and conclusive.
b. Appeal
In the event of an adverse benefit determination, you may appeal the adverse determination by giving written notice to the Plan Administrator within sixty (60) days after receipt of the notice of adverse benefit determination. The Plan Administrator may hold a hearing or otherwise ascertain such facts as it deems necessary and shall render a decision which shall be binding upon both parties. The appeal procedure shall:
1.
Provide you at least 60 days following receipt of a notification of an adverse benefit determination within which to appeal the determination;
2.
Provide you the opportunity to submit written comments, documents, records, and other information relating to the claim for benefits;
3.
Provide that you shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to your claim for benefits; and
4.
Provide for a review that takes into account all comments, documents, records, and other information submitted by you relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination.
The decision of the Plan Administrator shall be made within sixty (60) days after the receipt by the Plan Administrator of the notice of appeal, unless special circumstances require an extension of time for processing, in which case a decision of Cerner shall be rendered as soon as possible but not later than one hundred twenty (120) days after receipt of the request for review. If such an extension of time is required, written or electronic notice of the extension shall be furnished to you prior to the commencement of the extension. The decision of the Plan Administrator shall be provided in written or electronic form to you and shall include the following:
1.
The specific reason or reasons for the adverse determination;
2.
Reference to the specific plan provisions on which the benefit determination is based;
3.
A statement that you are entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to your claim for benefits. Whether a document, record, or other information is relevant to a claim for benefits shall be determined by reference to DOL Regulation Section 2560.503-1 (m)(8); and
4.
A statement describing any voluntary appeal procedures offered by the Plan and your right to obtain the information about such procedures, and a statement of your right to bring an action under ERISA section 502(a).
Section 10. Statement of ERISA Rights
The following statement is required by federal statute. Certain portions of this statement may not apply to your particular situation or to this Plan.
a. Information About This Plan and Your Benefits
If you become a participant in the Cerner Corporation Enhanced Severance Pay Plan you are entitled to certain rights and protections under the Employee Retirement Income Security Act of 1974 (ERISA). ERISA provides that all Plan participants shall be entitled to:
Examine, without charge, at the Plan Administrator's office and at other specified locations, the Plan documents and, if any, copies of all documents filed by the Plan with the U.S. Department of Labor, such as detailed annual reports and plan descriptions.
Obtain copies of all Plan documents and other plan information upon written request to the Plan Administrator. The Plan Administrator may make a reasonable charge for the copies.
Receive a summary of the Plan's annual financial report, if one is required to be prepared. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report if an annual report is required to be filed with the Department of Labor.





b. Prudent Actions by Plan Fiduciaries
In addition to creating rights for plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate your plan, called "fiduciaries" of the plan, have a duty to do so prudently and in the interest of you and other plan participants and beneficiaries. No one, including your employer or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA.
c. Enforce Your Rights
If your claim for a Plan benefit is denied in whole or in part you must receive a written explanation of the reason for the denial. You have the right to have the Plan review and reconsider your claim. Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request materials from the Plan and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or federal court. If it should happen that plan fiduciaries misuse the plan's money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.
d. Assistance with Your Questions
If you have any questions about this Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, you should contact the nearest office of the Employee Benefits and Security Administration, U.S. Department of Labor, listed in your telephone directory, or the Division of Technical Assistance and Inquiries, Employee Benefits and Security Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210.
Section 11. Additional Information
a. Name and Address of Plan Sponsor and Plan Administrator
The name and address of the Plan Sponsor and the Plan Administrator is:

Cerner Corporation
2800 Rockcreek Parkway
North Kansas City, MO 64117
EIN: 43-1196944
Telephone: (816) 201-1024

b. Type of Administration
The Plan is administered by Cerner Corporation
c. Plan Number
The Plan number is 513
d. Plan Year
The Plan Year ends on December 31
e. Agent For Service of Legal Process
Service of legal process may be made upon the Plan Sponsor (which is also the Plan Administrator) at the above address.
f. Plan Costs
Plan costs are paid by Cerner. The Plan is funded out of Cerner's general assets.
g. Insurance
Benefits provided by this Plan are not insured by the Pension Benefit Guaranty Corporation under Title IV of ERISA because the insurance provisions under ERISA are not applicable to the Plan.





Section 12. Governing Law
This Plan is an "employee welfare benefit plan" within the meaning of Section 3(1) of ERISA and it shall be interpreted, administered, and enforced in accordance with that law. To the extent that state law is applicable, the statutes and common law of the State of Missouri, excluding any that mandate the use of another jurisdiction's laws, shall apply. Without limiting the generality of this Section 12, it is intended that the Plan comply with Section 409A of the Code, and, in the event that this Plan is determined to be a "deferred compensation plan" within the meaning of Section 409A(d)(1) of the Code, Cerner shall, as necessary, adopt such conforming amendments as are necessary to comply with Section 409A of the Code.
Section 13. Basis of Payments to and From the Plan
The Plan shall be unfunded, and all cash payments under the Plan shall be paid only from the general assets of Cerner
Section 14. Limitation on IRC Section 280G Parachute Payments
In the event that any Severance Benefit payment to be made under this Plan would cause an Eligible Associate to be liable for any excise tax under Code section 4999(a), the aggregate amount of such Severance Benefit shall be reduced by the minimal amount necessary such that the Eligible Associate is no longer subject to such excise tax. Any determination or calculation made by Cerner relating to this Section 14, including, but not limited to, any calculation of an Eligible Associate's "base amount" as defined in Code section 280G(b)(3), or an Eligible Associate's anticipated "parachute payment," as defined in Code section 280G(b)(2), shall be final, conclusive and binding on the Eligible Associate
Section 15. Construction
Where the context so indicates, the singular will include the plural and vice versa. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of the Plan. Unless the context clearly indicates to the contrary, a reference to a statute or document shall be construed as referring to any subsequently enacted, adopted, or executed counterpart.






Exhibit A
Severance Matrix Effective October 1, 2017
Years of Service Role Level
Less than 2 Years
Severance Weeks
>2, less than 5 Years
Severance Weeks
>5, less than 10 Years
Severance Weeks
>10 Years
Severance Weeks
Executive Committee / Executive Officers [1]  / EVP
16
24
36
52
Senior Vice President
13
20
30
42
Vice President
10
16
24
32
Senior Director
8
14
21
28
Director
6
12
18
24
Levels [*]  2 and 3
4
8
12
16
Levels [*]  4 and 5
3
6
9
12
Levels [*]  6, 7 and 8
2
4
6
8
[1] "Executive officer" shall have the meaning ascribed to such term in Rule 3b-7 promulgated under the Securities Exchange Act of 1934, as amended, and shall include those persons designated as "executive officers" by the Cerner Corporation Board of Directors from time to time.
[*] Until this Exhibit A is otherwise amended, for the purpose of determining Severance Weeks under this Severance Matrix, the applicable level is the level the Associate held on October 1, 2017.





Exhibit 10.2
CERNER CORPORATION
2011 OMNIBUS EQUITY INCENTIVE PLAN - NONQUALIFIED STOCK OPTION GRANT CERTIFICATE

The Compensation Committee of the Board of Directors or its duly appointed subcommittee or authorized delegatee (the "Committee") of Cerner Corporation (the "Company" - which term includes its subsidiaries wherever applicable) has determined that Optionee is eligible to receive an option to purchase shares of Common Stock of the Company under the Company’s 2011 Omnibus Equity Incentive Plan, as Amended & Restated May 22, 2015 (the "Plan"), as so indicated on the Notice of Stock Option Grant, and the Committee authorizes and directs the grant of such an option to Optionee pursuant to the following terms and conditions, and subject to any other specifically agreed to terms and conditions that may exist in Optionee's employment agreement with the Company, which shall govern over this Grant Certificate.

1.
Grant of Option . Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Grant Certificate, the Company grants to Optionee an option (the "Option") to purchase from the Company all or any part of an aggregate number of shares of Company Common Stock designated as "Option Shares" in the Notice of Stock Option Grant at a price per share equal to the Exercise Price in the Notice of Stock Option Grant. The Notice of Stock Option Grant, the Vesting Schedule related to this award and this Grant Certificate (together, the "Grant Agreement") set forth the terms of the Option award granted to Optionee. The effective date written in the Notice of Stock Option Grant shall be deemed to be the Granting Date of this Option.

2.
Incorporation of the Plan . A copy of the Plan is incorporated herein by reference and all of the terms, conditions and provisions contained therein shall be deemed to be contained in this Grant Certificate.

3.
Term of Option . Optionee may purchase all or any portion of the Option Shares subject to each tranche listed in the Vesting Schedule in the Grant Agreement at any time on or after the Exercise Dates listed therein and before the Expiration Date (or any earlier termination date).

This Option shall expire with respect to all Option Shares ten (10) years from the Granting Date (the "Expiration Date"), unless it shall be terminated at an earlier date in accordance with this Grant Certificate.

This Option shall expire with respect to all unvested Option Shares immediately upon termination of Optionee’s employment or engagement with the Company or any of its subsidiaries.

This Option shall expire as to all vested but unexercised Option Shares ninety (90) calendar days after termination of Optionee's employment or engagement with the Company or any of its subsidiaries, except that in the event such employment or engagement is terminated: (a) by reason of Optionee's retirement (pursuant to the Company's then current employment practices), death or disability, then Optionee, or Optionee's estate, shall have twelve (12) months following such termination date to exercise this Option as to the number of Option Shares vested and exercisable on such termination date, or (b) for cause, including without limitation, Optionee’s dishonesty, illegal conduct or breach of the Company's policies ("Cause"), the Option shall terminate with respect to all vested but unexercised Option Shares immediately upon such termination.

In the event of a "Change of Control" as defined in the Plan: (i) 50% of Optionee’s outstanding Option Shares that have not yet vested shall immediately vest (such 50% shall be comprised of 50% of each tranche of all unvested Option Shares with different vesting dates); and, (ii) all remaining Option Shares shall continue to vest according to the current vesting schedule and terms of this Option, but should Optionee's employment or engagement be terminated by the Company, other than for Cause, or should Optionee resign for Good Reason (as defined in Optionee's employment agreement with the Company or in the Company’s then current Enhanced Severance Pay Plan), within twelve (12) months of the Change in Control, all such remaining Option Shares shall vest immediately.

Notwithstanding the foregoing, and except to the extent any contrary or overriding term would result in a violation of Internal Revenue Code Section 409A, to the extent that (i) Optionee’s employment agreement contains terms and conditions relating to the vesting or forfeiture of equity awards, including this Option, and (ii) a provision in such employment agreement directly conflicts with any provision in this Section 3, the terms and conditions set forth in such employment agreement shall supersede and control.






4.
Exercise of Option . This Option may be exercised by Optionee delivering to the Company a written notice of exercise along with: (a) payment in the amount of the Exercise Price for such shares, plus (b) the amount of any Applicable Withholding Taxes (as defined in the Plan) to be withheld and remitted or otherwise payable by Optionee or Company in connection with such options and/or their vesting/exercise. The payment for the Exercise Price for the shares and Applicable Withholding Taxes may be made:

(a)
in cash,

(b)
by delivering shares owned by Optionee (including shares acquired in connection with the exercise of a previously granted option) having an aggregate fair market value on the date of exercise equal to the Exercise Price and Applicable Withholding Taxes, or

(c)
any other means allowable under the Plan which the Company in its sole discretion determines will provide legal consideration for the Shares and Applicable Withholding Taxes (including the exercise through a "cashless" exercise through an approved third-party broker).

5.
Notices . Any notices or other communications required or allowed to be made or given to the Company under the terms of this Grant Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to Optionee shall be addressed to Optionee at Optionee’s address on record with the Company. Either Company or Optionee may from time to time change the address to which notices are to be sent to Company or Optionee, respectively, by giving written notice of such change to the other. Any notice hereunder shall be deemed to have been duly given five business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States Government.

6.
Assignment . This Option shall not be assignable by Optionee without the express written consent of Company or in accordance with the Plan. The Company will maintain records of all stock option grants and exercises. In the event this Grant Certificate and such records do not agree, such records shall control.

7.
Governing Law . This Grant Certificate shall be construed in accordance with the laws of the State of Missouri.






Exhibit 10.3
CERNER CORPORATION 2011
2011 OMNIBUS EQUITY INCENTIVE PLAN - TIME BASED RESTRICTED STOCK AGREEMENT

(Continued from the "Notice of Grant Award and Award Agreement")

WHEREAS, the Compensation Committee of the Board of Directors or its duly appointed subcommittee or authorized delegatee (the "Committee") of Cerner Corporation ("the Company") has determined that Grantee ("Participant") is eligible to receive a Time-Based Restricted Stock Grant under the Company's 2011 Omnibus Equity Incentive Plan as Amended & Restated May 22, 2015 (the "Plan"), as so indicated in the Notice of Grant Award and Award Agreement, which together with this Time Based Restricted Stock Agreement, constitutes the "Agreement";

NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:

1.
Incorporation of the Plan . A copy of the Plan is incorporated herein by reference and all the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.

2.
Restricted Stock Grant . Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement and any other specifically agreed to terms and conditions that may exist in any employment agreement between Participant and the Company (which shall govern over this Agreement), the Company hereby grants to Participant a Time-Based Restricted Stock Award (the "Award") for the aggregate number of shares of Company Common Stock (the "Shares") set forth in the Notice of Grant Award. The date of grant of the Award (the "Grant Date") shall for all purposes be as set forth in the Notice of Grant Award.

3.
Rights as a Shareholder . Commencing on the Grant Date, Participant shall have the right to receive dividends and other distributions (if any) with respect to the Shares unless and until such Shares are forfeited pursuant to Section 5 hereof; provided, however, that a dividend or other distribution (including, without limitation, a stock dividend or stock split), other than a cash dividend or distribution, shall be delivered to the Company and shall be subject to the same vesting schedule and other terms, conditions and restrictions as the Shares with respect to which such dividend or other distribution was made. In connection with the payment of such dividends or other distributions, the Company may deduct any taxes or other amounts required by any governmental authority to be withheld and paid over to such authority for the account of Participant. Participant shall be entitled to retain cash dividends and distributions received regardless of whether the Shares with respect to which such dividends or distributions were made are subsequently forfeited pursuant to Section 5 hereof. Participant shall have no right to vote the Shares until such Shares are actually distributed on the Vest Date. Notwithstanding anything to the contrary, prior to the date on which the Shares and any related property received under Section 3 hereof (the “Aggregate Restricted Shares”) Vest pursuant to Section 5, such Aggregate Restricted Shares shall be subject to the restrictions on transferability contained in Section 6 hereof.

4.
Custody and Delivery of Shares . Unless otherwise requested by Participant, Aggregate Restricted Shares will be distributed in street name on the Vest Date and held in Participant’s account at Morgan Stanley or other broker that the Company may choose (the “Broker”). Prior to the Vest Date, the Grant of the Aggregate Restricted Shares will be recorded in the Company’s books and records. Company will reflect in its records the restrictions under which the Aggregate Restricted Shares are held and will not allow distribution or transfer of any Aggregate Restricted Shares prior to the date on which such Aggregate Restricted Shares Vest pursuant to Section 5 below. Shares, representing Vested Aggregate Restricted Shares, will be distributed only on or after the Vest Date and only if the requirements of Vesting set forth in Section 5 are met. The Company will pay all original issue or transfer taxes and all fees and expenses incident to the delivery of any Aggregate Restricted Shares hereunder.

5.
Vesting and Forfeiture . Except as otherwise provided in the Plan, this Agreement or any employment agreement between Participant and the Company, the Aggregate Restricted Shares subject to this Award shall be distributed, become transferable and shall cease to be subject to forfeiture ("Vest") on the date(s) set forth in the Notice of Grant Award (the "Vest Date") provided Participant remains an employee ("associate"), consultant or advisor of the Company from the Grant Date through the Vest Date set forth in the Notice of Grant Award. In the event of the death or disability of Participant prior to the Vest Date, and assuming Participant continuously served as an employee through the date of such death or disability, then the Aggregate Restricted Shares shall Vest on the Vest Date if the Vest Date occurs within ninety (90) days of such death or disability; otherwise the Aggregate Restricted Shares shall immediately terminate and be forfeited to the Company upon such death or disability. In the event





such Participant is terminated or resigns, then all Aggregate Restricted Shares that have not Vested as of such date shall immediately terminate and shall be forfeited to the Company. In the event of a "Change of Control" as defined in the Plan: (i) 50% of Participant’s outstanding Shares that have not yet Vested shall immediately Vest (such 50% shall be comprised of 50% of each tranche of all unvested Shares with different Vest dates); and, (ii) all remaining Shares shall continue to Vest according to the current vesting schedule and terms of this Award, but should Participant's employment or engagement be terminated by the Company, other than for Cause, or should Participant resign for Good Reason (as defined in Participant's employment agreement with the Company or in the Company's then current Enhanced Severance Pay Plan), within twelve (12) months of the Change in Control, all such remaining Shares shall Vest immediately. Notwithstanding the foregoing, and except to the extent any contrary or overriding term would result in a violation of Code Section 409A, to the extent that (i) the employment agreement between Participant and the Company contains terms and conditions relating to the Vesting or forfeiture of equity awards, including the Shares, and (ii) a provision in such employment agreement directly conflicts with any provision in this Section 5, the terms and conditions set forth in such employment agreement shall supersede and control.

6.
Non-Transferability of Shares . Prior to the date on which the Aggregate Restricted Shares Vest pursuant to Section 5 hereof, such Aggregate Restricted Shares may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Any such attempted sale, transfer, assignment, pledge, hypothecation or encumbrance, or other disposition of such Aggregate Restricted Shares shall be null and void.

7.
Securities Laws . Participant hereby represents and covenants that if in the future Participant decides to offer or dispose of any Aggregate Restricted Shares or interest therein, Participant will do so only in compliance with this Agreement, the Securities Act of 1933, as amended, and all applicable state securities laws. As a condition precedent to the delivery to Participant of the Aggregate Restricted Shares, Participant shall comply with all regulations and requirements of any regulatory authority having control or supervision over the issuance of the Aggregate Restricted Shares and, in connection therewith, shall execute any documents and make any representation and warranty to the Company which the Committee shall in its sole discretion deem necessary or advisable.

8.
Taxable Income. Participant may file an election for immediate Federal income taxation pursuant to Section 83(b) of the Internal Revenue Code. In the event that Participant makes an election pursuant to Section 83(b) of the Code, Participant agrees to notify the Company thereof in writing within ten (10) days after such election; any necessary withholding at the time of an 83(b) election must not be made from Vested Shares, but must be a cash withholding, from either wages or a separate payment. THE FEDERAL INCOME TAX CONSEQUENCES DESCRIBED ABOVE ARE FOR GENERAL INFORMATION ONLY. EACH PARTICIPANT SHOULD CONSULT A TAX ADVISOR AS TO THE SPECIFIC FEDERAL INCOME TAX CONSEQUENCES AND AS TO THE SPECIFIC CONSEQUENCES UNDER STATE, LOCAL AND FOREIGN TAX LAWS.

9.
Withholding with Shares. Unless specifically denied by the Committee, Participant may elect to pay all amounts of tax withholding, or any part thereof, by electing to have the Company withhold from the Vested Shares in the same tranche a number of Shares having a value equal to the amount to be withheld under federal, state or local law and in accordance with the Plan. The value of such Shares to be withheld by the Company shall be based on the Fair Market Value of the Shares on the date that the amount of tax to be withheld is to be determined (the "Tax Date"), as determined by the Committee. Any election by Participant to have such Shares withheld for this purpose will be subject to the following restrictions:

(a)
All elections must be made prior to the Tax Date;
(b)
All elections shall be irrevocable; and
(c)
If Participant is an officer or director of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), Participant must satisfy the requirements of Section 16 and any applicable rules thereunder with respect to the use of Shares to satisfy such tax withholding obligation.

10.
Notices . Any notices or other communications required or allowed to be made or given to the Company under the terms of this Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to Participant shall be addressed to Participant at the address in the Company’s records. Either party hereto may from time-to-time change the address to which notices are to be sent to such party by giving written notice of such change to the other party.





Any notice hereunder shall be deemed to have been duly given five (5) business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States government.

11.
Binding Effect and Assignment . This Agreement shall bind the parties hereto, but shall not be assignable by Participant.

12.
Governing Law . This Agreement shall be construed in accordance with the laws of the State of Missouri.

This Agreement has been issued by the Company by its duly authorized representatives and shall be effective as of the Grant Date set forth in the Notice of Grant Award.




Exhibit 10.4

CERNER CORPORATION 2011 OMNIBUS EQUITY INCENTIVE PLAN - PERFORMANCE-BASED RESTRICTED STOCK AGREEMENT

(Continued from the "Notice of Grant Award and Award Agreement")

WHEREAS, the Compensation Committee of the Board of Directors or its duly appointed subcommittee or authorized delegatee (the "Committee") of Cerner Corporation (the "Company") has determined that Grantee ("Participant") is eligible to receive a Performance-Based Restricted Stock Grant under the Company's 2011 Omnibus Equity Incentive Plan, as Amended & Restated May 22, 2015 (the "Plan"), as so indicated in the Notice of Grant Award and Award Agreement, which together with this Performance Based Restricted Stock Agreement, constitutes the "Agreement";

NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:

1.
Incorporation of the Plan . A copy of the Plan is incorporated herein by reference and all the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.

2.
Restricted Stock Grant . Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement and any other specifically agreed to terms and conditions that may exist in any employment agreement between Participant and the Company (which shall govern over this Agreement), the Company hereby grants to Participant a Performance-Based Restricted Stock Award (the "Award") for the aggregate number of shares of Company Common Stock (the "Shares") as set forth in the Notice of Grant Award. The date of grant of the Award (the "Grant Date") shall for all purposes be as set forth in the Notice of Grant Award.

3.
Rights as a Shareholder . Commencing on the Grant Date, Participant shall have the right to receive dividends and other distributions (if any) with respect to the Shares unless and until such Shares are forfeited pursuant to Section 5 hereof; provided, however, that a dividend or other distribution (including, without limitation, a stock dividend or stock split), other than a cash dividend or distribution, shall be delivered to the Company and shall be subject to the same vesting schedule and other terms, conditions and restrictions as the Shares with respect to which such dividend or other distribution was made. In connection with the payment of such dividends or other distributions, the Company may deduct any taxes or other amounts required by any governmental authority to be withheld and paid over to such authority for the account of Participant. Participant shall be entitled to retain cash dividends and distributions received regardless of whether the Shares with respect to which such dividends or distributions were made are subsequently forfeited pursuant to Section 5 hereof. Participant shall have no right to vote the Shares until such Shares are actually distributed on the Vest Date. Notwithstanding anything to the contrary, prior to the date on which the Shares and any related property received under Section 3 hereof (the "Aggregate Restricted Shares") Vest pursuant to Section 5, such Aggregate Restricted Shares shall be subject to the restrictions on transferability contained in Section 6 hereof.

4.
Custody and Delivery of Shares . Unless otherwise requested by Participant, Aggregate Restricted Shares will be distributed in street name on the Vest Date and held in Participant’s account at Morgan Stanley or other broker that the Company may choose (the "Broker"). Prior to the Vest Date, the Grant of the Aggregate Restricted Shares will be recorded in the Company's books and records. Company will reflect in its records the restrictions under which the Aggregate Restricted Shares are held and will not allow distribution or transfer of any Aggregate Restricted Shares prior to the date on which such Aggregate Restricted Shares Vest pursuant to Section 5 below. Shares, representing Vested Aggregate Restricted Shares, will be distributed only on or after the Vest Date and only if the requirements of Vesting set forth in Section 5 are met. The Company will pay all original issue or transfer taxes and all fees and expenses incident to the delivery of any Aggregate Restricted Shares hereunder.

5.
Vesting and Forfeiture . Except as otherwise provided in the Plan, this Agreement or any employment agreement between Participant the Company, the Aggregate Restricted Shares subject to this Award shall be distributed, become transferable and shall cease to be subject to forfeiture ("Vest') upon the achievement of the objective and subjective performance goals set forth in the Notice of Grant Award, subject to the restrictions set forth in the Notice of Grant Award (the "Vest Date") provided Participant remains an employee ("associate"), consultant or advisor of the Company from the Grant Date through the Vest Date. This Grant will expire if Participant has not reached the performance goals, as set forth in the Notice of Grant Award by the Vest Date. Should Participant’s





employment or engagement terminate, for any reason, then all Aggregate Restricted Shares that have not Vested as of such date of termination shall immediately terminate and shall be forfeited to the Company. In the event of a "Change of Control" as defined in the Plan: (i) 50% of Participant’s outstanding Shares that have not yet Vested shall immediately Vest (such 50% shall be comprised of 50% of each tranche of all unvested Shares with different Vest Dates); and, (ii) all remaining Shares shall continue to Vest according to the current vesting schedule and terms of this Award, but should Participant’s employment or engagement be terminated by the Company, other than for Cause, or should Participant resign for Good Reason (as defined in Participant’s employment agreement with the Company or in the Company’s then current Enhanced Severance Pay Plan), within twelve (12) months of the Change in Control, all such remaining Shares shall Vest immediately. Notwithstanding the foregoing, and except to the extent any contrary or overriding term would result in a violation of Code Section 409A, to the extent that (i) the employment agreement between Participant and the Company contains terms and conditions relating to the Vesting or forfeiture of equity awards, including the Shares, and (ii) a provision in such employment agreement directly conflicts with any provision in this Section 5, the terms and conditions set forth in such employment agreement shall supersede and control.

6.
Non-Transferability of Shares . Prior to the date on which any Aggregate Restricted Shares Vest pursuant to Section 5 hereof, such Aggregate Restricted Shares may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Any such attempted sale, transfer, assignment, pledge, hypothecation or encumbrance, or other disposition of such Aggregate Restricted Shares shall be null and void.

7.
Securities Laws . Participant hereby represents and covenants that if in the future Participant decides to offer or dispose of any Aggregate Restricted Shares or interest therein, Participant will do so only in compliance with this Agreement, the Securities Act of 1933, as amended, and all applicable state securities laws. As a condition precedent to the delivery to Participant of the Aggregate Restricted Shares, Participant shall comply with all regulations and requirements of any regulatory authority having control or supervision over the issuance of the Aggregate Restricted Shares and, in connection therewith, shall execute any documents and make any representation and warranty to the Company which the Committee shall in its sole discretion deem necessary or advisable.

8.
Taxable Income. Participant may file an election for immediate Federal income taxation pursuant to Section 83(b) of the Internal Revenue Code. In the event that Participant makes an election pursuant to Section 83(b) of the Code, Participant agrees to notify the Company thereof in writing within ten (10) days after such election; any necessary withholding at the time of an 83(b) election must not be made from Vested Shares, but must be a cash withholding, from either wages or a separate payment. THE FEDERAL INCOME TAX CONSEQUENCES DESCRIBED ABOVE ARE FOR GENERAL INFORMATION ONLY. EACH PARTICIPANT SHOULD CONSULT A TAX ADVISOR AS TO THE SPECIFIC FEDERAL INCOME TAX CONSEQUENCES AND AS TO THE SPECIFIC CONSEQUENCES UNDER STATE, LOCAL AND FOREIGN TAX LAWS.

9.
Withholding with Shares .   Unless specifically denied by the Committee, Participant may elect to pay all amounts of tax withholding, or any part thereof, by electing to have the Company withhold from the Vested Shares in the same tranche a number of Shares having a value equal to the amount to be withheld under federal, state or local law and in accordance with the Plan. The value of such Shares to be withheld by the Company shall be based on the Fair Market Value of the Shares on the date that the amount of tax to be withheld is to be determined (the "Tax Date"), as determined by the Committee.  Any election by Participant to have such Shares withheld for this purpose will be subject to the following restrictions:

(a)
All elections must be made prior to the Tax Date;
(b)
All elections shall be irrevocable; and
(c)
If Participant is an officer or director of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), Participant must satisfy the requirements of Section 16 and any applicable rules thereunder with respect to the use of Shares to satisfy such tax withholding obligation.

10.
Notices . Any notices or other communications required or allowed to be made or given to the Company under the terms of this Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to Participant shall be addressed to Participant at the address in the Company’s records. Either party hereto may from time-to-time change the address to which notices are to be sent to such party by giving written notice of such change to the other party.





Any notice hereunder shall be deemed to have been duly given five (5) business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States government.

11.
Clawback . Participant acknowledges that the Award may be subject to certain provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 ("Dodd-Frank") that will require the Company to recover certain amounts of incentive compensation paid to certain executive officers if the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirements under any applicable securities laws. By accepting this Award, Participant agrees and consents to any forfeiture or required recovery or reimbursement obligations of the Company with respect to any equity paid to Participant under this Agreement that is forfeitable or recoverable by the Company pursuant to Dodd-Frank and in accordance with any Company policies and procedures adopted by the Compensation Committee in order to comply with Dodd Frank, even if such policies or procedures are adopted after the grant date of this Award and as the same may be amended from time to time.

12.
Binding Effect and Assignment . This Agreement shall bind the parties hereto, but shall not be assignable by Participant.

13.
Governing Law . This Agreement shall be construed in accordance with the laws of the State of Missouri.

This Agreement has been issued by the Company by its duly authorized representatives and shall be effective as of the Grant Date as set forth in the Notice of Grant Award.




Exhibit 10.5

 
 
Notice of Grant of Award

Cerner Corporation
and Award Agreement

ID:   43-1196944

 
2800 Rockcreek Parkway


 
North Kansas City, MO 64117-2551


 
 
Grantee: [Associate Name]

Award Number: [Grant Number]


[Address]

Plan: Omni


 
 


You have been granted an award of Restricted Stock Units ("RSUs") by Cerner Corporation (the "Company") as follows:
 
Grant Date:
[____]
 
 
Total Number of RSUs Granted:
[____]
 
 
 
 
Each RSU represents the right to receive one share of the Company’s common stock, $0.01 par value (each a "Share") if the vesting terms and conditions set forth in the Agreement and Omnibus Plan (as such terms are defined below) are met.

 
 
 
Type of RSU:

Time-based RSUs

 
 
 
Vesting Schedule:

Shares
Vest Date
 
[____]

[____]

 
 
 
Manner of Payment by Company:

Subject to the continuous employment vesting condition noted below, on the Vest Date, the vested RSUs shall be settled by issuing a number of Shares equal to the number of RSUs vesting on such Vest Date

In addition to the above-discussed time-based vesting condition(s), but subject to any other specifically agreed to terms and conditions that may exist in any employment agreement you enter into with the Company (which shall govern over this Agreement), you must be continuously employed by the Company through the applicable Vest Date(s) for the RSUs to vest and the Shares to be deposited into your account. Should your employment with the Company terminate, for any reason, prior to the Vest Date(s), any RSUs that have not vested as of such termination of employment and the right to receive the Shares relating thereto shall be immediately forfeited except as specifically set forth in any employment agreement you enter into with the Company (which shall govern over this Agreement).

By your acceptance of this award of RSUs, you agree and understand that this award is granted under and governed by the terms and conditions of Cerner Corporation’s 2011 Omnibus Equity Incentive Plan, as Amended and Restated May 22, 2015 (as amended, the "Omnibus Plan"), this Notice of Grant of Award and Award Agreement, and the attached Time-Based RSU Agreement (together, the "Agreement"). A copy of the Prospectus relating to the Omnibus Plan is also attached.






CERNER CORPORATION 2011 OMNIBUS EQUITY INCENTIVE PLAN - TIME-BASED RSU AGREEMENT

(Continued from the Notice of Grant of Award and the RSU Award Agreement)

WHEREAS, the Compensation Committee of the Board of Directors or its duly appointed subcommittee or authorized delegatee (the "Committee") of Cerner Corporation (the "Company") has determined that Grantee ("Participant") is eligible to receive a Time-Based Restricted Stock Unit ("RSU") Grant under the Company's 2011 Omnibus Equity Incentive Plan, as Amended & Restated May 22, 2015 (the "Plan"), as so indicated in the Notice of Grant of Award, which together with any RSU Award Agreement and this Time-Based RSU Agreement, constitutes the "Agreement";

NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:

1.
Incorporation of the Plan . A copy of the Plan is incorporated herein by reference and all the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.

2.
RSU Grant . Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement and any other specifically agreed to terms and conditions that may exist in any employment agreement between Participant and the Company (which shall govern over this Agreement), the Company hereby grants to Participant a Time-Based RSU Award (the "Award") upon the Vesting of which Participant will be paid an aggregate number of shares of Company Common Stock (the "Shares") as set forth in the Notice of Grant of Award. The date of grant of the Award (the "Grant Date") shall for all purposes be as set forth in the Notice of Grant of Award.
 
3.
Rights as a Shareholder . Participant shall have no right to receive actual dividends or other distributions (if any) with respect to the RSUs; provided, however , that if a dividend or other distribution (including, without limitation, a stock dividend) shall be made on Shares, dividend equivalents equal to the amount and type of property that otherwise would have been transferred to Participant if each RSU was an actual Share shall be credited and accumulated in a non-interest bearing Company bookkeeping account and shall be subject to the same vesting schedule and other terms, conditions and restrictions as the RSUs on which such dividend equivalents relate. In connection with the payment of any dividend equivalents, the Company may deduct any taxes or other amounts required by any governmental authority to be withheld and paid over to such authority for the account of Participant. Participant shall have no shareholder voting rights with respect to any RSUs unless and until Shares are actually distributed in connection with the Vesting of the RSUs. Notwithstanding anything to the contrary, prior to the date on which the RSUs and any dividend equivalents received under Section 3 hereof (the "Aggregate RSU Consideration") Vest pursuant to Section 5, such Aggregate RSU Consideration shall be subject to the restrictions on transferability contained in Section 6 hereof.

4.
Custody and Delivery of Shares . Unless otherwise requested by Participant, any Share issued pursuant to this Agreement in connection with the Vesting and settlement of an RSU will be distributed in street name on or within 30 days following the Vest Date and held in Participant’s account at Morgan Stanley or other broker that the Company may choose (the “Broker”). Prior to the Vest Date, the grant of the RSUs will be recorded in the Company’s books and records. Company will reflect in its records the restrictions under which the Aggregate RSU Consideration is held and will not allow distribution or transfer of any Aggregate RSU Consideration prior to the date on which such Aggregate RSU Consideration Vests pursuant to Section 5 below. Shares will be distributed only on or after the Vest Date, only if the requirements of Vesting set forth in this Agreement are met and only if the Committee elects to settle the RSU by payment of a Share. The Company will pay all original issue or transfer taxes and all fees and expenses incident to the delivery of any Aggregate RSU Consideration hereunder.

5.
Vesting and Forfeiture . Except as otherwise provided in the Plan, this Agreement or any employment agreement between Participant and the Company, the Aggregate RSU Consideration subject to this Award shall be distributed, become transferable and shall cease to be subject to forfeiture ("Vest" or "Vesting") on the date(s) and in the amounts set forth in the Notice of Grant of Award (the "Vest Date") provided Participant remains an employee ("associate"), consultant or advisor of the Company from the Grant Date through the Vest Date as defined in the Notice of Grant of Award. This Grant will expire, in part or in whole as applicable, if Participant's employment or other service relationship with Company ends before the Vest Date for any reason (other than on account of death or disability within period described below). In the event of the death or disability of Participant within the ninety (90) day period immediately preceding the Vest Date, and assuming Participant continuously served as an





associate, consultant or advisor through the date of such death or disability, then the Aggregate RSU Consideration with respect to the RSUs scheduled to Vest on such Vest Date shall Vest on the date of such death or disability; otherwise the Award shall immediately terminate with respect to any then unvested RSUs and the remaining Aggregate RSU Consideration shall be forfeited to the Company upon such death or disability. In the event such Participant is terminated or resigns, then any unvested portion of the Award and unvested Aggregate RSU Consideration shall immediately terminate and shall be forfeited to the Company. In the event of a "Change of Control" as defined in the Plan: (i) 50% of Participant’s outstanding Shares that have not yet Vested shall immediately Vest (such 50% shall be comprised of 50% of each tranche of all unvested Shares with different Vest dates); and, (ii) all remaining Shares shall continue to Vest according to the current vesting schedule and terms of this Award, but should Participant’s employment or engagement be terminated by the Company, other than for Cause, or should Participant resign for Good Reason (as defined in Participant’s employment agreement with the Company or in the Company's then current Enhanced Severance Pay Plan), within twelve (12) months of the Change in Control, all such remaining Shares shall Vest immediately. Notwithstanding the foregoing, and except to the extent any contrary or overriding term would result in a violation of Code Section 409A, to the extent that (i) the employment agreement between Participant and the Company contains terms and conditions relating to the Vesting or forfeiture of equity awards, including the RSUs, and (ii) a provision in such employment agreement directly conflicts with any provision in this Section 5, the terms and conditions set forth in such employment agreement shall supersede and control.

6.
Non-Transferability of Award . Prior to the date on which any Aggregate RSU Consideration Vests pursuant to Section 5 hereof, none of the RSUs nor any right to receive a Share upon the settlement thereof, nor any other rights to receive any Aggregate RSU Consideration, may be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Any such attempted sale, transfer, assignment, pledge, hypothecation or encumbrance, or other disposition of such Aggregate RSU Consideration or any rights relating thereto shall be null and void.

7.
Securities Laws . Participant hereby represents and covenants that if in the future Participant decides to offer or dispose of any Shares obtained in connection with the Vesting of an RSU, Participant will do so only in compliance with this Agreement, the Securities Act of 1933, as amended, and all applicable state securities laws. As a condition precedent to the delivery to Participant of the Aggregate RSU Consideration, Participant shall comply with all regulations and requirements of any regulatory authority having control or supervision over the issuance of the Aggregate RSU Consideration and, in connection therewith, shall execute any documents and make any representation and warranty to the Company which the Committee shall in its sole discretion deem necessary or advisable.

8.
Withholding with Shares.   Unless specifically denied by the Committee, Participant may elect to pay all amounts of tax withholding, or any part thereof, by electing to have the Company withhold from the Shares otherwise eligible to be issued in connection with the Vesting of an RSU from the same RSU tranche a number of Shares having a value equal to the amount to be withheld under federal, state or local law and in accordance with the Plan. The value of such Shares to be withheld by the Company shall be based on the Fair Market Value of the Shares on the date that the amount of tax to be withheld is to be determined (the "Tax Date"), as determined by the Committee.  Any election by Participant to have such Shares withheld for this purpose will be subject to the following restrictions: 

(a)
All elections must be made prior to the Tax Date;
(b)
All elections shall be irrevocable; and
(c)
If Participant is an officer or director of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), Participant must satisfy the requirements of Section 16 and any applicable rules thereunder with respect to the use of Shares to satisfy such tax withholding obligation.

9.
Notices . Any notices or other communications required or allowed to be made or given to the Company under the terms of this Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to Participant shall be addressed to Participant at the address in the Company’s records. Either party hereto may from time-to-time change the address to which notices are to be sent to such party by giving written notice of such change to the other party. Any notice hereunder shall be deemed to have been duly given five (5) business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States government.






10.
Binding Effect and Assignment . This Agreement shall bind the parties hereto, but shall not be assignable by Participant.

11.
Governing Law . This Agreement shall be construed in accordance with the laws of the State of Missouri.

This Agreement has been issued by the Company by its duly authorized representatives and shall be effective as of the Grant Date as set forth in the Notice of Grant of Award.





Exhibit 10.6

CERNER CORPORATION 2011 OMNIBUS EQUITY INCENTIVE PLAN - PERFORMANCE-BASED RSU AGREEMENT

(Continued from the "Notice of Grant of Award")

WHEREAS, the Compensation Committee of the Board of Directors or its duly appointed subcommittee or authorized delegatee (the "Committee") of Cerner Corporation ("the Company") has determined that Grantee ("Participant") is eligible to receive a Performance-Based Restricted Stock Unit ("RSU") Grant under the Company's 2011 Omnibus Equity Incentive Plan, as Amended & Restated May 22, 2015 (the "Plan"), as so indicated in the Notice of Grant of Award, which together with any RSU Award Agreement and this Performance Based RSU Agreement, constitutes the "Agreement";

NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:

1.
Incorporation of the Plan . A copy of the Plan is incorporated herein by reference and all the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.

2.
RSU Grant . Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement and any other specifically agreed to terms and conditions that may exist in any employment agreement between Participant and the Company (which shall govern over this Agreement), the Company hereby grants to Participant a Performance-Based RSU Award (the "Award") upon the Vesting of which Participant will be paid an aggregate number of shares of Company Common Stock (the "Shares") as set forth in the Notice of Grant of Award. The date of grant of the Award (the "Grant Date") shall for all purposes be as set forth in the Notice of Grant of Award.

3.
Rights as a Shareholder . Participant shall have no right to receive actual dividends or other distributions (if any) with respect to the RSUs; provided, however, that if a dividend or other distribution (including, without limitation, a stock dividend) shall be made on Shares, dividend equivalents equal to the amount and type of property that otherwise would have been transferred to Participant if each RSU was an actual Share shall be credited and accumulated in a non-interest bearing Company bookkeeping account and shall be subject to the same vesting schedule and other terms, conditions and restrictions as the RSUs on which such dividend equivalents relate. In connection with the payment of any dividend equivalents, the Company may deduct any taxes or other amounts required by any governmental authority to be withheld and paid over to such authority for the account of Participant. Participant shall have no shareholder voting rights with respect to any RSUs unless and until Shares are actually distributed in connection with the Vesting of the RSUs. Notwithstanding anything to the contrary, prior to the date on which the RSUs and any dividend equivalents received under Section 3 hereof (the “Aggregate RSU Consideration”) Vest pursuant to Section 5, such Aggregate RSU Consideration shall be subject to the restrictions on transferability contained in Section 6 hereof.

4.
Custody and Delivery of Shares . Unless otherwise requested by Participant, any Share issued pursuant to this Agreement in connection with the Vesting and settlement of an RSU will be distributed in street name on or within 30 days following the Vest Date and held in Participant’s account at Morgan Stanley or other broker that the Company may choose (the "Broker"). Prior to the Vest Date, the grant of the RSUs will be recorded in the Company's books and records. Company will reflect in its records the restrictions under which the Aggregate RSU Consideration is held and will not allow distribution or transfer of any Aggregate RSU Consideration prior to the date on which such Aggregate RSU Consideration Vests pursuant to Section 5 below. Shares will be distributed only on or after the RSU Vest Date, only if the requirements of Vesting set forth in Section 5 are met and only if the Committee elects to settle the RSU by payment of a Share. The Company will pay all original issue or transfer taxes and all fees and expenses incident to the delivery of any Aggregate RSU Consideration hereunder.

5.
Vesting and Forfeiture . Except as otherwise provided in the Plan, this Agreement or any employment agreement between Participant and the Company, the Aggregate RSU Consideration subject to this Award shall be distributed, become transferable and shall cease to be subject to forfeiture ("Vest" or "Vesting") upon the achievement of the objective performance goals set forth in the Notice of Grant of Award, subject to the restrictions set forth in the Notice of Grant of Award (the "Vest Date") provided Participant remains an employee ("associate"), consultant or advisor of the Company from the Grant Date through the Vest Date. This Grant will expire, in part or in whole as





applicable, if achievement of the objective performance goals as set forth in the Notice of Grant of Award is not completed by the Vest Date. Should Participant’s employment or engagement terminate, for any reason, then all Aggregate RSU Consideration that has not Vested as of such date of termination shall immediately terminate and shall be forfeited to the Company. In the event of a "Change of Control" as defined in the Plan: (i) 50% of Participant’s outstanding Shares that have not yet Vested shall immediately Vest (such 50% shall be comprised of 50% of each tranche of all unvested Shares with different Vest dates); and, (ii) all remaining Shares shall continue to Vest according to the current vesting schedule and terms of this Award, but should Participant’s employment or engagement be terminated by the Company, other than for Cause, or should Participant resign for Good Reason (as defined in Participant’s employment agreement with the Company or in the Company’s then current Severance Pay Plan), within twelve (12) months of the Change in Control, all such remaining Shares shall Vest immediately. Notwithstanding the foregoing, and except to the extent any contrary or overriding term would result in a violation of Code Section 409A, to the extent that (i) the employment agreement between Participant and the Company contains terms and conditions relating to the Vesting or forfeiture of equity awards, including the RSUs, and (ii) a provision in such employment agreement directly conflicts with any provision in this Section 5, the terms and conditions set forth in such employment agreement shall supersede and control.

6.
Non-Transferability of Award . Prior to the date on which any Aggregate RSU Consideration Vests pursuant to Section 5 hereof, none of the RSUs nor any right to receive a Share upon the settlement thereof, nor any other rights to receive any Aggregate RSU Consideration, may be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Any such attempted sale, transfer, assignment, pledge, hypothecation or encumbrance, or other disposition of such Aggregate RSU Consideration or any rights relating thereto shall be null and void.

7.
Securities Laws . Participant hereby represents and covenants that if in the future Participant decides to offer or dispose of any Shares obtained in connection with the Vesting of an RSU, Participant will do so only in compliance with this Agreement, the Securities Act of 1933, as amended, and all applicable state securities laws. As a condition precedent to the delivery to Participant of the Aggregate RSU Consideration, Participant shall comply with all regulations and requirements of any regulatory authority having control or supervision over the issuance of the Aggregate RSU Consideration and, in connection therewith, shall execute any documents and make any representation and warranty to the Company which the Committee shall in its sole discretion deem necessary or advisable.

8.
Withholding with Shares.   Unless specifically denied by the Committee, Participant may elect to pay all amounts of tax withholding, or any part thereof, by electing to have the Company withhold from the Shares otherwise eligible to be issued in connection with the Vesting of an RSU from the same RSU tranche a number of Shares having a value equal to the amount to be withheld under federal, state or local law and in accordance with the Plan. The value of such Shares to be withheld by the Company shall be based on the Fair Market Value of the Shares on the date that the amount of tax to be withheld is to be determined (the "Tax Date"), as determined by the Committee. Any election by Participant to have such Shares withheld for this purpose will be subject to the following restrictions:

(a)
All elections must be made prior to the Tax Date;
(b)
All elections shall be irrevocable; and
(c)
If Participant is an officer or director of the Company within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), Participant must satisfy the requirements of Section 16 and any applicable rules thereunder with respect to the use of Shares to satisfy such tax withholding obligation.

9.
Notices . Any notices or other communications required or allowed to be made or given to the Company under the terms of this Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to Participant shall be addressed to Participant at the address in the Company’s records. Either party hereto may from time-to-time change the address to which notices are to be sent to such party by giving written notice of such change to the other party. Any notice hereunder shall be deemed to have been duly given five (5) business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States government.






10.
Clawback . Participant acknowledges that the Award may be subject to certain provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 ("Dodd-Frank") that will require the Company to recover certain amounts of incentive compensation paid to certain executive officers if the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirements under any applicable securities laws. By accepting this Award, Participant agrees and consents to any forfeiture or required recovery or reimbursement obligations of the Company with respect to any equity paid to Participant under this Agreement that is forfeitable or recoverable by the Company pursuant to Dodd-Frank and in accordance with any Company policies and procedures adopted by the Compensation Committee in order to comply with Dodd Frank, even if such policies or procedures are adopted after the grant date of this Award and as the same may be amended from time to time.

11.
Binding Effect and Assignment . This Agreement shall bind the parties hereto, but shall not be assignable by Participant.

12.
Governing Law . This Agreement shall be construed in accordance with the laws of the State of Missouri.

This Agreement has been issued by the Company by its duly authorized representatives and shall be effective as of the Grant Date as set forth in the Notice of Grant of Award.





Exhibit 10.10

Relocation Agreement

TO
Jeff Townsend (000522)
 
 
 
 
 
 
FROM
Global Mobility
 
 
 
 
 
 
DATE
February 8, 2017
 
 
 
 
 
 
SUBJECT
Relocation Agreement
 
 
 
 
 
 

This Relocation Agreement (this "Agreement") sets out the arrangements of your relocation from Smithville, MO to Park City, UT. The terms and conditions of your relocation are strictly confidential and must be held so by you and any other party who has access to the relocation arrangements, unless otherwise required by applicable law. All terms and conditions of your relocation are governed by this Agreement and the U.S. Relocation Guideline for Homeowners (the "Guideline"), which is attached hereto as Exhibit A and incorporated into this Agreement by reference. Any exceptions to the Guideline are explicitly noted in this Agreement. Capitalized terms used but not defined herein are defined in the Guideline. Please review and sign below to indicate your agreement with the terms of this Agreement.

Relocation Assistance

1.
Cerner will provide Home Maintenance Reimbursement (HMR) of $6,000 USD per year to be paid on a quarterly basis. This amount is recoverable per the Repayment Provision of this Agreement.

2.
Cerner will provide a Home Leave Allowance of $14,000 USD per year for personal travel to be paid on a quarterly basis. This amount is recoverable per the Repayment Provision of this Agreement.

Return to Origin

3.
Cerner will provide a Relocation Allowance of $10,000 USD to return to Kansas City. This amount is recoverable per the Repayment Provision of this Agreement.

4.
Cerner will arrange for the shipment of personal goods from Park City, UT back to your residence in Smithville, MO in accordance with the Guideline.

5.
Cerner will provide Home Sale Assistance up to $70,000 for the residence in Park City as defined in the supplemental U.S. Homeowner BVO/Direct Reimbursement Relocation Guideline. This amount is recoverable per the Repayment Provision of this Agreement.

Repayment Provision

6.
You agree that in the event employment with Cerner terminates voluntarily or involuntarily for cause within two (2) years from the date any recoverable mobility benefit was received, the associated relocation benefits are 100% recoverable during the first year and recoverable on a 12-month prorated basis during the second year. Recoverable benefits are explicitly noted as such in this Agreement. Cerner reserves the right to offset such amounts owed to Cerner against all salary, bonuses, vacation pay, expense reimbursements and other Cerner monies owed to the Associate, as allowable by law. Cerner also reserves the right to collect such amounts through legal means if necessary.






By signing below, you agree to the terms and conditions of the Guideline and this Agreement. A signed Agreement must be received by Global Mobility before any assignment benefits will be initiated. This Agreement is your entire agreement with Cerner concerning the subject matter hereof, and this Agreement cancels, terminates and supersedes any of your previous oral or written understandings or agreements with Cerner or with any director, officer or representative of Cerner with respect to your relocation. Cerner has the right, in its sole discretion, to amend and/or terminate this Agreement and/or the Guideline at any time.



/s/Jeff Townsend
 
2/8/2017
 
 
Jeff Townsend
 
Date
 
 
 
 
 
 
 
 
 
 
 
 
/s/Brandee Faille
 
2/8/2017
 
 
Brandee Faille, Director, Global Mobility
 
Date
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 





Exhibit A

U.S. Homeowner Direct Reimbursement Guideline

The U.S . Homeowner - Direct Reimbursement Relocation Guideline (the "Guideline") is a guide for associates of Cerner Corporation and its affiliated entitie s ("Cerner") who are consider ing or have accepted an offer involving relocation within the U . S., and a resource for managers and others responsible for administering Global Mobility programs. Cerner reserves the right to change any components of this Guideline at any time .

Program Overview and Objectives

This benefit is available to associates who are homeowners in the sending location and i s only available once the relocation has been approved. The Associate should not contact or make any commitments to a real estate agent prior to initiation with Gra ebe l. Cerner has contracted with Graebel, a national relocation service, to ass i st associates in se lling their hom es. The Associate will receive assistance in selecting the best possible real estate agent, developing a marketing st r ategy, monitoring the marketing plan, negotiating the sale and coordinating all aspects of closing.

The objectives of th e program are to benefit the Associate by: (1) increasing the As soc iate 's ability to secure the highest sale price possible; (2) decreasing the cost to the Associate of customary seller paid expenses; (3) ensuring a timely receipt of the closing cost s reimbursement; (4) eliminating as much time and hassle associated with the home sale process as possible; and (5) resettling the family in the new location in a shorter time frame.

Guidelines and Limitations

To accomplish the objectives of the program a nd to ensure eligibility for all benefits , the Associate agrees that:

1.
The Associate will not list the home prior to initiation into the Graebel program;
2.
The Associate will adhere to the program procedures as set forth by Cerner and Graebel; and
3.
The residence is owned and occupied by the Associate and is classified as a single - family r es idence, two- family (duple x) , a condominium or town hou se.

How to Get Started

Upon Initiation with Grae beI, an assig ned Graebel Relocation Consultant (hereinafter "G ra e bel'') will contact the Associate and the following steps will then occur:

1.
Realtor Selection: All real estate brokers mu st either be referred by or pre-qualified by Graebel as an approved rea l estate broker of their program . Cerner does not reimbur se the Associate, immediate family member, or other relativ e for the fees associated with the listin g or sa l e of the Associate's property.
2.
Broker Market Analysis (BMA): Graebel will coordinate getting two Broker Market Analy ses from Graebel ref er r ed or approved real estate brokers prior to l is ting the home. Th e BMAs must be within 5% of each other. If the BM As are not within 5% of each other , Graebel will di sc uss the discrepancy with the realtor s and, if nece ssa ry , request a third BMA from an additional broker.
3.
Home/Seller Data Collection : Graebel and the Associate's real estate broker will collect current information from the A ssocia t e about the home s uch as a Se ller's Disclosure State m e nt, Home Owner's Association requirements and fees, and/or Lead Based Paint Disclo s ure.

Home Sale Process

The following represent s the process followed by Cerner and Graebel to manage the sa le of the home:

1.
Listing the property and establishing a marketing strategy - Upon Graebel's Relocation Consultant's receipt of the required documents from the Associate , the following will occur :

a.
The Associate and Graebel will agree upon the real estate agent who will receive the listing, and the Associate will execute the listing agreement, including the following Exclusion Clause in the additional provisions section: "Either party may terminate this agreement at any time, for any rea so n . "






b.
The Associate and Graebel will agree upon the listing price and marketing plan to be implemented based on the data obtained from the BMAs , including any repairs to be completed to expedite the selling proces s . The listing pri ce cannot exceed 102 % of the highest recommended listing price as noted in the BMAs . An updated BMA will be ordered every 90 days, and the list price should then be adjusted to within 102% of the updated most likely sa les price.

2.
Receiving agent marketing updates and providing feedback - Graebel is an advocate for the Associate and will ensure all actions are directed at accomp l ishing a successful sale. Consistent communication between the agent and Graebel, while keeping the Associate informed, will maximize the opportunity for a quick sale at an acceptable price to the Associate. The agent is required to send a bi-weekly marketing report to Graebel for review, and Graebel will communicate any recommendations for price changes, concessions, interior or exterior updates, etc. to make the home more appealing to buyers.

3.
Offer Negotiation - Upon receipt of an offer, the Associate should work with his/her real estate agent and the Graebel Relocation Consultant to develop any necessary counter offers or acceptance.

4.
Closing Coordination - The closing between the Associate and th e buyer will take place upon the date agreed to in the original executed offer . The Associate will attend the closing with the real estate agent and sign the appropriate documents. The Associate is responsible for maintaining the property and making any necessary mortgage , tax, utility or HOA payments up through the date of the closing with the buyer. The A ss ociate must submit to Cerner a co py of the final , executed HUD-1 settlement st atement upon the completion of closing as this will be required for reimbursement.

The following fees are considered normal and customary Seller's closing costs and will be reimbursed to the Associate with appropriate documentation:
Closing Costs
Reimbursable
Broker's Commission up to 6%
X
Title Charges
X
Attorney Fees
X
Escrow Fees
X
Document Preparation Fee
X
Mortgage Release Fees
X
State/Local Transfer Tax (up to 1/2%)
X
Recording Fees
X
Closing/Other Legal Fees
X
Miscellaneous Courier Fees
X

5.
Receiving Home Sale Reimbursement - Once the Associate has attended and completed the closing of the home, the Associate must submit the final signed HUD-1 settlement statement to the Gra e bel Relocation Consultant for reimbursement, along with a signed and dated Graebel expense form. Only normal and customary Seller's closing costs and commissions up to 6% will be reimbursed based on the associate ' s fle xib le budget . The Associate may request payment in the form of a check or a direct deposit to a bank account. Reimbursement will be processed and sent out within 72 hours of receipt of the correct and appropriate documents and forms.





U.S. HOMEOWNER BVO RELOCATION GUIDELINE

The U.S. Homeowner - BVO (Buyer Value Option) Relocation Guideline ("Guideline") is a guide for associates of Cerner Corporation and its affiliated ent i ties ( " Cerner " ) who are considering or have accepted an offer involving relocation within the U.S., and a resource for managers a nd others responsible for administering relocation programs . Cerner reserves th e right to change any components of this Guideline at any time.

Program Overview and Objectives

This benefit is available to associates who are homeowners in the sending location and is only available once the relocation has been approved . The Associate should not contact or make any commitments to a real estate agent prior to i nitiation with Graebel. Cerner has contracted with Graebel, a national relocation service, to assist associates in selling their homes. The Associate will receive help in selecting the best possible real estate agent, developing a marketing st rategy , monitoring the marketing plan, negotiating the sale and coordinating a ll aspects of closing .

The objections of the program are to benefit the As s ociate by: (1) increasing the Associate's ability to secure the highest sale price possible; (2) eliminating the cost to the Associate of customary seller paid expenses; (3) ensuring a timely closing on the home in the new location; (4) ensuring the Associate receives accurate and timely receipt of proceeds; (5) eliminating as much time and hassle associated with the home safe proces s as possible; (6) resettling the family in the new location in a shorte r time frame; and (7) reducing income tax liability through effective process management.

Guidelines and Limitations

To accomplish the objectives of the program and to ensure eligibility for all benefits, the Associate agrees that:

1.
The Associate will not list the home prior to in itiation i nto the Graebel program;
2.
The Associate will adhere to the program pro cedures as set forth by Cerner and Graebel; and
3.
The residence is owned and occupied by the Associate and is classified as a single - family residence, two-family (duplex), condominium or town house.

How to Get Started

Upon initiation with Graebel, an assigned Graebel Relocation Consultant (hereinafter "Grae bel' ') will contact the Associate an d the following steps will then occur:

1.
Realtor Selection: All real estate brokers must either be referred by or pre-qualified by Graebel as an approved real estate broker of their program. Cerner does not reimburse the Associate, immediate family member, or other relative for the fees associated with the fisting or sale of the Associate's property.
2.
Broker Market Analysis (BMA): Graebel will coordinate getting two Broker Market Analyses from Graebel referred or approved real estate bro kers prior to listing the home . The BMAs must be within 5% of each other. If the BMAs are not within 5 % of each other, Graebel will discuss the discrepancy with the realtors and, if necessary, request a third BMA from an additional broker.
3.
Home/Seller Data Collection : Graebel and the Associate's real estate broker will collect current information from the Associate about the home such as a Seller's Disclo sure Statement, Home Owner's Association requirements and fees, and/or Lead Based Paint Disclosure .
4.
Pre-sale Home lnspection(s): Graebel will coordinate and arrange for any necessary inspection(s) prior to selling the home and all repairs ident ified in the inspection must be addressed appropriately. The BVO program requires the Associate to complete all repairs and/or agree to have the repair costs withheld from the Associate's final home equity prior to the closing of the sale to Graebel/Cerner.

Home Sale Process

The following represents the process followed by Cerner and Graebel to manage the sale of the home:

1.
Listing the property and establishing a marketing strategy - Upon Graebel's receipt of the required documents, the following will occur:






a.
The As s ociate and Graebel will agree upon the real estate agent who will receive the listing , and the Associate will execute the listing agreement, including the following Exclusion Clause in the additional provisions section : " Either party may terminate this agreement at any time , for any reason . "

b.
The Associate and Graebel will agree upon the listing price and marketing plan to be implemented ba s ed on the data obtained from the BMAs , including any repairs to be completed to expedite the selling process. The listing price cannot exceed 102% of the highest recommended listing price as noted in the BMAs . An updated BMA will be ordered every 90 days , and the list price should then be adju s ted to within 102% of the updated most likely sale pric e .

c.
Preliminary title will be ordered and upon receipt , the A ss ociate will be made aware of any title encumbrances that must be cleared prior to sale (at the Associate's expense).

d.
Cerner's policy and the recommended BVO proto c ol require that a property inspection be conducted prior to taking title to the property , if not completed prior to listing, which is preferred. The Associate will be responsible for making any necess a ry repairs a s indicated by the inspection s , or the cost for such repairs can be withheld from the Associate's final equity .

2.
Receiving agent marketing updates and providing feedback - Graebel i s an advocate for the Associate and will en s ure all actions are directed at accomplishing a s uccessful sale.

a.
Consistent communication between the agent and Graebel, while keeping the Associate informed, will ma x imi z e the opportunity for a quick sale at an acceptable price to the Associate .

b.
The agent is required to send a bi-weekly marketing report to Graebel for review .

c.
Graebel will communicate any recommendations for price changes, concessions, interior or exterior updates, etc. to make the home more appealing to buyers.

3.
Offer Negotiation - Graebel should be notified immediately upon receipt of any and all prospective buyer offers by the listing agent . Ne x t st e p s are a s follow s:

a.
Graebel will contact the Associate to discuss th e term s and condition s and work with the real estate broker to counter or accept the offer.

b.
Once the negotiations are comp l eted and both the Assoc i ate and buyer agree on terms and conditions of the purchase agreement, Graebel will ask the Associate to execute the Residential Property Purchase Agreement (RPPA) , a contract between the Associate and Graebel/Cerner , which will mirror the contract negotiated with the outside buy e r.

c.
The Associate must sign and return thi s RPPA to Graebel as soon a s possible. The ultimate contract between Graebel and the outside buyer cannot be executed and considered "Under Contract" until the As s ociate has returned the fully e x ecuted RPPA.

4.
Closing Coordination - The closing between the Associate and Graebel will occur no less than twenty-four (24) hours prior to the scheduled closing between Graebel and the ultimate buyer. This closing date will be established based on the latter of the signature date on the RPPA, or the vacate date. The Associate is responsible for all costs associated with the property up thro ugh the date of closing, including , but not limited to, pro-rations for taxes, interest on mortgage, utilities, homeowner's insurance, repairs required from inspections, and any concessions agreed upon with the buyer. The Associate will re ceive an Equity Statement showing the amount of equity due from the sale and the Associate will be paid out equity as soo n as possible following the closing date with Graebel.






The following fees are cons idere d normal and customary Seller's closing costs and will be reimbursed to the Associate with appropriate document ation :

Closing Costs
Reimbursable
Broker's Commission up to 6%
X
Title Charges
X
Attorney Fees
X
Escrow Fees
X
Document Preparation Fee
X
Mortgage Release Fees
X
State/Local Transfer Tax (up to 1/2%)
X
Recording Fees
X
Closing/Other Legal Fees
X
Miscellaneous Courier Fees
X

5.
Vacating the Property - The Associate must vacate the property at least twenty-four (24) hours prior to the closing date agreed upon with the outside buyer, or sooner. The Associate is responsible for utilities, general maintenance and insurance on household goods through the date of va cating or possession to Graebel. If the Associate is vacating on or before the 10th of the month, the Associate SHOULD NOT make a mortgage payment . If the Associate is vacating on or after the 11th of the month, the Associate SHOULD make a mortgage payment. Graebel will provide instructions for transfer of utilities, keys, etc. to the real estate agent .

6.
If the Sale to Outside Buyer Falls Through - Graebel, on behalf of Cerner , has acquired the property as of the date of closing; therefore, in the event that a sale to an outside buyer falls through, the property is owned by Cerner and Graebel will be responsible for the resale of the property. Any outstanding equity funds due to the Associate will be paid within ten (10) days of the "closing date" with Graebel. Therefore, it is understood that upon closing of a transaction wherein Graebel purchases the Associate 's property, Graebel sha ll thereafter bear all financial risk associated with the property. Please note that in the case Graebel on behalf of Cerner takes the home into inventory due to the outside buyer contract falling through, mortgage(s) on the property will not be paid in full . Mortgage, HOA, tax, utility payments , etc will be made on a monthly basis by Graebel's inventory department.

7.
Taxes - I f the Associate participates in the Buyer Value Option (BVO) Home Sa le program, the Associate will not incur any additional tax burden for expenses incurred with the sale of the current residence. No add it ional compensation to reimburse tax liability will be made to any associate who chooses to operate outside of the procedures and polices described herein and who receives reimbursement for any nondeductible expenses incurred in disposing of their current home .





U.S. RELOCATION GUIDELINE FOR HOMEOWNERS

As Cerner Corporation and its affiliates ("Cerner") expand dome st ically, it is sometimes necessary and ad v antageous to relocate associate s to various locations. Relocations are appropriate in situations where Cerner needs to establish a presence in a local market , provide the necessary skills for local requirement s, or balance resources across the U.S. When Cerner formall y requests a candidate or associate to cons ider relocation, financia l ass i stance will be provided to facilitate the move . The U.S. Relocation Guideline for Homeowners (the " Guide li ne ") offers a full range of benefit options that can be customized to meet the needs of the Associate.

The purpose of this Guideline is to document the components of relocation assistance, which will be considered in each Cerner requested relocation. Each component will be evaluated indiv i dually based on the specific circ u mstances of the relocation , may or may not be applicable, and may be capped based on the total relocation budget. Cerner and the Associate will work togethe r to make effective use of the required funds while minimizing costs to the Associate and Cerner.

Administration and Eligibility

Cerner's relocation benefits are administered by Human Resources and through Cerner's relocation provider, Graebel. All requests for relocation assistance should be directed to Global Mobility prior to any relocation activities taking place. Global Mobility and/or Graebel will process all payments or reimbur sements for relocation expenses.

This Guideline applies to newly hired or curren t associates who move at the request of Cerner. The Associa te 's move must meet the IRS 50 - Mile Rule to qualify for relocation assistance, which means that the di s tance between the Associate's former residence and new place of employment must be 50 miles more than the distance between the Associate's former residence and former place of employment. The IRS 50-Mile Rule also requires that the Ass oci ate's move be made within (twelve) 12 months from the hire or transfer date , and all relocation benefits will expire twelve (12) months from that date. In the event a move has not taken place within twelve (12) months from the Associate ' s hire or transfer date, all re location benefits will be forfeited and any relocation benefits already distributed will be 100% r ecovera ble according to the Repa yme nt Provision of this Agreement .

The Associate is automatically eligible for the Core Benefit s listed below. The Fle x ible Benefits are granted as the As s ociate's total relocation budget will allow.

Core Benefits

Relocation Allowance

The relocation allowance should be used to cover expen ses associated w ith house hunting trips, temporary l ivi ng , movement of goods, and the final move of the Associate to the receiving location. Graebel will issue the relocation allowance within thirty (30) days of the Associate's hire or transfer date.

Tax Considerations

Th e relocation allowance amount represents taxable income and the total relocation e xp ense will also include the add itional taxes the Associate owes as a result of this payment. These amounts are reflected in the appropriate withholding tax boxes on the Associate' s form W-2 at the conclusion of the ta x year. Cerner pay s/w ithholds the taxes on the Associate's behalf so the net relocation allowance is received at the time of relocation. The relocation allowance amount and the additional tax payment make up th e total relocat io n expense, however, and t he Associate will be responsible for repayment of the entire amount under the Repa yme nt Provision of this Guide line, as applicable.

Flexible Benefits

Shipment of Personal Goods

Graebel will make arrangements for a moving company to contact the Associate to begin this process. Cerner will pay the expenses of a full - service move from the current location to the receiving location, including packin g , insurance and transit. Please see the table below for specific services that Cerner will provide as a part of this benefit . This amount will be direct-billed to Cerner through our corporate account with United Van Line. The final shipment invoice amount will be recoverable according to the Repayment Provision of the Guideline.





Cerner will Provide
Cerner will NOT Provide
Packing

Overtime Charges on Nights and Weekends
Loading and Un l oad i ng

Storage Greater than 30 Days
Transporting Goods
Transporting of Collections (i.e. jewelry, stamp, wine , etc . )
3rd  party service s for*: Washer/Dryer/Refrigerator Hook Ups, Piano, Grandfather Clock, Waterbed, Pool Table
3 rd Party Service s for : Hot Tub, Basketball Goal, Swing Sets , Additional Wiring for Washer/Dryer/Refrigerator , Exercise Equipment, Computer/ Audio Systems, Light Fi x tures, Fireplace Doors, Satellite Dishes
*as long as these items are being utilized at origin
30 Days Storage - Household Goods Only

Storage of Autos

Replacement Value Insurance

Transportation of the following items: Firewood, Lumber, Flammable Items , Guns , Ammunition , Pets, Plants
Wa s te Management- 1 Trip

Tran s portation of Boats and Other Recreational Vehicles
Stair Carry - If necessary

Transportation of Hot Tubs
Elevator Charge s - If necessary

 
Shuttle Service - If necessary

 
Automobiles :
 
- 1 car
 
- 2 cars if move is greater than 1000 miles
 
Crating and Uncrating of all Televisions (Plasma, LCD,
or a ny other HDTV that requires crating)
 

-OR-

If th e Associate selects a self - servic e move (i . e . U-Haul , Penske, Budget, etc . ) , Cerner will cover the cost of a truck/trailer, tow dolly , auto transport and insurance . The Graebel Relocation Con s ultant will work with the associate on how to submit expenses for reimbursement.

NOTE: The move should be accomplished as economically as possible, while minimizing any personal inconvenience and lost time .

Time-Off

Cerner may provide up to two (2) days of administrative time-o ff for internal move s to be taken prior to departure or upon arrival to the new location . Time - off must be used within thirty (30) days of transfer date . Time-off should be coordinated with the Associate's manager(s) to ensure busin es s needs are not negatively impact e d.

Home Purchase Assistance

Realtor Selection

All real -e s tate brokers must either be re ferred by or pre - qualified by Graebel as an approved rea ltor of their program. Cerner does not reimburse an associate, immediate family member, or other re lat ive for the fees associated with the lis ting or sa le of an associate's property. If the Associate elects to use a realtor from Graebel's nationwide realtor database , Graebel will obtain a referral fee and in turn , pass on savings to Cerner. The savings will help to reduce the total dollars spent on Cerner's relocation. Per request, a Graebel Relocation Consultant can pro vide Cerner associates a li st of local agents who specialize in assisting associates who are re loca ti ng from another location.






Loan/Home Purchase Origination Fee

Th e following sliding scale will define the associate's eligibility to receive payment for loan /h ome purchase Origination Fee s ("Points") for the purchase of a home in the receiving location.

Interest Rate
Cerner Allowable Origination Fee
0-8%
None
8-9%
1%
10-+%
2-5%

Direct Bill-Home Purchase Closing Costs

All eligible closing costs will be direct billed to Cerner and/or Graebel if the associate elects to use one of the l enders that Cerner and/or Graebel has a partnership with.

Home Purchase Adm i nistrative Costs

If the Associate purchases a home in the receiving location within twelve (12) months of the effective date o f the relocation, the Associate is eligible to receive payment for the following administrative costs:

Category
Reimbursable by Cerner
Non-reimbursable by Cerner
Items Payable in Connection with Loan
Loan/Home Purchase Origination Fee
X (See sliding scale above)
 
Loan Discount
 
X
Appraisal Fee
X
 
Credit Report
X
 
Lender's Inspection Fee
X
 
Mortgage Insurance App Fee
 
X
Assumption Fee
 
X
Commitment Fee
 
X
Application Fee
X
 
Underwriting Fee
X
 
Funding Fee
 
X
Items Required by Lender to Be Paid in Advance
Mortgage Insurance Premium
 
X
Title Charges
Settlement/Closing Fee
X
 
Abstract/Title Search
X
 
Title Examination
X
 
Title Insurance Binder
X
 
Documentation Prep
X
 
Notary Fees
X
 
Attorney's Fees
Lender's
X
 
 
(When state required. Up to maximum of 1% of purchase price or $1000, whichever is less and in lieu of Associate missing work to finalize closing)
 
Borrower's
X (Same as lender's attorney limits)
 





Title Insurance
Lender's Coverage
X
 
Owner's Coverage
X
 
Government Recording
Recording Fee
X
 
City/County Tax/Stamp
X
 
State Tax/Stamp
X
 
Additional Settlement Charges
Survey
X
 
Pest Inspection
X
 
Other Miscellaneous Charges
Tax Service Fee
X
 
Express (Courier) Service
X
 
Septic/Well Inspection
X (If required by lender)
 
Flood Plain Certificate
X
 
Home Inspection
X
 
Engineering Inspection
X (If required by lender)
 
Roof Inspection
X (If required by lender)
 
Radon Inspection
X (If required by lender)
 

Home Sale Assistance

P l ea se note that the Home Sale As si stan c e benefit is de s cribed in th e following s upplemental gu i delines :

U . S . Homeowner - Direct Reimbursement Relo c ation Guideline
U . S . Homeowner- BVO Relocation Gu i d e lin e

Duplicate Housing Reimbursement

The A ss ociate will be reimbur s ed for the lesser of the two payment s (mortgage at origin and m ortgage or le a se at d es tination) based on the fle xi ble bud g et. The r eimbur s ement amount is calculated using the ta x es and intere s t due to th e Asso c iate's mortgage comp a ny(s) and the total l e ase payment. The calculation doe s not i nclude any ut i lities, Hom e owner 's As s ociation due s , or additional fee s paid in addition to taxe s and intere s t. Duplic a te housing r e imbur s em e n ts ar e co n s id e red ta x abl e i ncome and will be gros s ed-up .

Repayment Provision

The Associat e understands and agree s that i n the event employment w i th Cerner t e rminates volunt a rily or i nvolunta r ily for cause within two (2) yea rs fro m the A ss ociat e ' s hir e date, tran s fer date or assi g nme n t s tart d a t e (a s applicable) , t he relocation and/or as s ignment benefits are 100 % recoverabl e during the first year and recoverable on a 12 - month prorated basi s dur i ng the se c ond year. Re c overable benefits will be noted in the Associate' s Offer Letter, R e loc a tion Agreement, Mobility Agreement or Ass ig nment Agreement (a s applicable). Cerner re s erve s the right to offset s uch a mount s owed to Cerner a g ainst all s alary , bonu s es, vacation pay , e x pense reimbursement s and other Cerne r moni es ow e d to the A ss o ci ate. Cerner al s o r e s e rv es the right to coll ec t such amount s through legal means if nec es sary.

Amendment or Termination

Cerne r has the r i ght , in it s s ole di sc retion to am e nd thi s Guideline or to terminate it at any time , for any reason or no rea s on at all. Thi s Guidel ine s hall not be considered or c on s trued a s an emp l oym e nt c ontract . Furthermor e, thi s Guideline does not confer upon the Associate any right to continued employment, nor doe s it supersede the Associate's individual Employment Agreement or Cerner's administrative practices.






Miscellaneous

Cerner shall decide disputes related to the rights under this Guideline with respect to any and all parties . In deciding such disputes, Cerner shall have full and complete discretionary authority to (i) construe and interpret the provisions of the Guideline and to determine the right of any person to any interest in or eligibility for any pay , reimbursement or other benefit under the Guideline, and (ii) make any and all factual determinations necessary to determine the right of any person to any interest i n or eligibility for any pay , reimbursement or other benefit under the Guideline , and no person shall be entitled to any pay, reimbursement or other benefit under this Guideline if Cerner decides in its discretion that there is no entitlement to that pay , reimbursement or other benefit. This Guideline shall be governed in accordance with the laws of the State of Missouri for U.S . associates and the law s of the state, province or equivalent jurisdiction of the applicable Cerner offices in the home location, for all other associates .









Exhibit 31.1
CERTIFICATION
I, Clifford W. Illig, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Cerner Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)         designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)         designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)         evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)         disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)         all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)         any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
 
 
 
 
 
 
 
 
Date: October 27, 2017
 
 
 
 
 
/s/Clifford W. Illig                    
 
 
 
 
 
 
 
 
Clifford W. Illig
 
 
 
 
 
 
 
 
Interim Chief Executive Officer
 
 
 
 
 
 
 
 
(Principal Executive Officer)
 
 




Exhibit 31.2
CERTIFICATION
I, Marc G. Naughton, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Cerner Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)         designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)         designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)         evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)         disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)         all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)         any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
 
 
 
 
 
 
 
 
Date: October 27, 2017
 
 
 
 
 
/s/Marc G. Naughton                     
 
 
 
 
 
 
 
 
Marc G. Naughton
 
 
 
 
 
 
 
 
Chief Financial Officer
 
 
 
 
 
 
 
 
(Principal Financial Officer)
 
 




Exhibit 32.1
CERTIFICATION FURNISHED PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2017 (the "Report") by Cerner Corporation (the "Company"), the undersigned Interim Chief Executive Officer of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
1.
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
/s/Clifford W. Illig                              
Clifford W. Illig, Chairman of the Board
and Interim Chief Executive Officer
(Principal Executive Officer)
Date: October 27, 2017




Exhibit 32.2
CERTIFICATION FURNISHED PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the filing of the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2017 (the "Report") by Cerner Corporation (the "Company"), the undersigned Chief Financial Officer of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
1.
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
/s/Marc G. Naughton                                
Marc G. Naughton, Executive Vice President
and Chief Financial Officer
(Principal Financial Officer)
Date: October 27, 2017